

09/700397

532 Rec'd PCT/PTO 14 NOV 2000

LAW OFFICES
SUGHRUE, MION, ZINN, MACPEAK & SEAS, PLLC
2100 PENNSYLVANIA AVENUE, N.W.
WASHINGTON, DC 20037-3213
TELEPHONE (202) 293-7060
FACSIMILE (202) 293-7860
www.sughrue.com

November 14, 2000

BOX PCT

Assistant Commissioner for Patents
Washington, D.C. 20231

PCT/JP99/02485
-filed May 13, 1999

Re: Application of Daikichi FUKUSHIMA, Shiro SHIBAYAMA and Hideaki TADA
NOVEL POLYPEPTIDES, cDNA ENCODING THE SAME, AND USE OF THEM
Our Ref: Q61459

Dear Sir:

The following documents and fees are submitted herewith in connection with the above application for the purpose of entering the National stage under 35 U.S.C. § 371 and in accordance with Chapter II of the Patent Cooperation Treaty:

- an executed Declaration and Power of Attorney.
- an English translation of the International Application and Declaration of the Translator.
- thirty-nine (39) pages of Sequence Listing.
- Notification Concerning Submission or Transmittal of Priority Document.
- International Preliminary Examination Report (foreign language).
- an executed Assignment and PTO 1595 form.
- International Search Report, Information Disclosure Statement, Form PTO-1449, and a complete copy of each reference.

It is assumed that copies of the International Application, and any Articles 19 and 34 amendments as required by § 371(c) will be supplied directly by the International Bureau, but if further copies are needed, the undersigned can easily provide them upon request.


The Government filing fee is calculated as follows:

Total claims	<u>11</u>	-	<u>20</u>	=	<u></u>	x	\$18.00	=	<u>\$0.00</u>
Independent claims	<u>1</u>	-	<u>3</u>	=	<u></u>	x	\$80.00	=	<u>\$0.00</u>
Base Fee									<u>\$860.00</u>
Multiple Dependent Claim Fee									<u>\$270.00</u>

TOTAL FILING FEE	<u>\$1130.00</u>
Recordation of Assignment	<u>\$40.00</u>
TOTAL FEE	<u>\$1170.00</u>

Checks for the statutory filing fee of \$1130.00 and Assignment recordation fee of \$40.00 are attached. You are also directed and authorized to charge or credit any difference or overpayment to Deposit Account No. 19-4880. The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.492 which may be required during the entire pendency of the application to Deposit Account No. 19-4880. A duplicate copy of this transmittal letter is attached.

Priority is claimed from May 14, 1998 based on Japanese Application No. P. Hei. 10-131815.

Respectfully submitted


Mark Boland
Registration No. 32,197

MXB/amt

(Box Sealed)

PATENT APPLICATION

PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Daikichi FUKUSHIMA, et al.

Appln. No.: 09/700,397

Filed: November 14, 2000



Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

For: NOVEL POLYPEPTIDES, cDNA ENCODING THE SAME, AND USE OF THEM

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination, please amend the above-identified application as follows:

IN THE SPECIFICATION:

Please amend the specification as follows:

Page 5, line 14, after "SEQ ID NOS." please delete "1" and insert --3--,

Page 5, line 15, please delete "6, 9 or 12" and insert --8, 11 or 14--,

Page 5, line 17, after "SEQ ID NOS." please delete "2, 5, 7, 10" and insert --1, 5, 6, 9--,

Page 5, line 18, please delete "13" and insert --12--,

Page 5, line 19, after "SEQ ID NOS." please delete "3, 8, 11" and insert --2, 7, 10--,

Page 5, line 20, please delete "14" and insert --13--,

Page 5, line 22, after "SEQ ID NOS." please delete "1" and insert --3--,

Page 5, line 23, please delete "6, 9 or 12" and insert --8, 11 or 14--,

Page 5, line 27, after "SEQ ID NOS." please delete "2, 5, 7, 10 or 13" and insert --1, 5, 6, 9 or 12--,

Page 5, line 29, after "SEQ ID NOS." please delete "2, 5, 7, 10, 13, 3, 8, 11 or 14" and insert --1, 5, 6, 9, 12, 2, 7, 10 or 13--,

Page 6, line 3, after "NOS." please delete "1, 4, 6, 9 or 12" and insert --3, 4, 8, 11 or 14--,

Page 6, line 5, after "SEQ ID NOS." please delete "1, 4, 6, 9" and insert --3, 4, 8, 11--,

PRELIMINARY AMENDMENT
Appln. No.: 09/700,397

Page 6, line 6, please delete "12" and insert --14--,

Page 6, line 8, after "SEQ ID NOS." please delete "1, 4, 6, 9 or 12" and insert --3, 4, 8, 11 or 14--,

Page 6, line 15, after "SEQ ID NOS." please delete "1, 4, 6, 9 or 12" and insert --3, 4, 8, 11 or 14--,

Page 6, line 19, after "SEQ ID NOS." please delete "2, 5, 7, 10, 13, 3, 8, 11 or 14" and insert --1, 5, 6, 9, 12, 2, 7, 10 or 13--,

Page 6, line 26, after "SEQ ID NOS." please delete "2, 5, 7, 10, 13, 3, 8, 11 or 14" and insert --1, 5, 6, 9, 12, 2, 7, 10 or 13--,

Page 7, line 9, after "SEQ ID NOS." please delete "2, 5, 7, 10, 13, 3, 8, 11 or 14" and insert --1, 5, 6, 9, 12, 2, 7, 10 or 13--,

Page 8, line 7, after "SEQ ID NO." please delete "1" and insert --3--,

Page 8, line 11, after "SEQ ID NOS." please delete "1, 4, 6, 9" and insert --3, 4, 8, 11--,

Page 8, line 12, please delete "12" and insert --14--,

Page 8, line 20, after "NOS." please delete "1, 4, 6, 9 or 12" and insert --3, 4, 8, 11 or 14--,

Page 8, line 26, after "SEQ ID NOS." please delete "3, 8, 11" and insert --2, 7, 10--,

Page 8, line 27, please delete "14" and insert --13--,

Page 11, line 21, after "SEQ ID NOS." please delete "2, 5, 7, 10" and insert --1, 5, 6, 9--,

Page 11, line 22, please delete "13" and insert --12--,

Page 12, line 6, after "SEQ ID NOS." please delete "2, 5, 7, 10" and insert --1, 5, 6, 9--,

Page 12, line 7, please delete "13" and insert --12--,

Page 13, line 4, after "SEQ ID NOS." please delete "3, 8, 11 or 14" and insert --2, 7, 10 or 13--,

Page 13, line 19, after "SEQ ID NOS." please delete "2, 5, 7, 10 or 13" and insert --1, 5, 6, 9 or 12--,

Page 26, line 14, after the nucleic acid sequence, please insert --SEQ ID NO. 15--,

Page 27, line 25, after the nucleic acid sequence, please insert --SEQ ID NO. 16--,

Page 28, line 5, after "SEQ ID NO." please delete "3" and insert --2--,

Page 28, line 7, after "SEQ ID NOS." please delete "1, 2, 4 and 5" and insert --1, 3, 4 and 5--,

Page 28, line 19, after "SEQ ID NO." please delete "1" and insert --3--,

Page 29, line 4, after the nucleic acid sequence, please insert --SEQ ID NO. 17--,

Page 29, line 10, after "SEQ ID NO." please delete "8" and insert --7--,

PRELIMINARY AMENDMENT
Appln. No.: 09/700,397

Page 29, line 12, after “SEQ ID NOS.” please delete “6 and 7” and insert --6 and 8--,
Page 30, line 8, after the nucleic acid sequence, please insert --SEQ ID NO. 18--,
Page 30, line 17, after “SEQ ID NO.” please delete “11” and insert --10--,
Page 30, line 19, after “SEQ ID NOS.” please delete “9 and 10” and insert --9 and 11--,
Page 31, line 1, after “SEQ ID NO.” please delete “9” and insert --11--,
Page 31, line 4, after “SEQ ID NO.” please delete “9” and insert --11--,
Page 31, line 23, after the nucleic acid sequence, please insert --SEQ ID NO. 19--,
Page 32, line 1, after “SEQ ID NO.” please delete “14” and insert --13--,
Page 32, line 3, after “SEQ ID NOS.” please delete “12 and 13” and insert --12 and 14--,

and

Page 32, line 14, after “SEQ ID NO.” please delete “12” and insert --14--.

IN THE CLAIMS:

Please amend the claims as follows:

Claim 1, line 2, after “SEQ ID NOS.” please delete “1, 4, 6, 9 or 12” and insert --3, 4, 8, 11 or 14--,

Claim 2, line 2, after “SEQ ID NOS.” please delete “1, 4, 6, 9 or 12” and insert --3, 4, 8, 11 or 14--,

Claim 4, line 2, after “SEQ ID NOS.” please delete “2, 5, 7, 10 or 13” and insert --1, 5, 6, 9 or 12-- and

Claim 5, line 2, after “SEQ ID NOS.” please delete “3, 8, 11 or 14” and insert --2, 7, 10 or 13--.

PRELIMINARY AMENDMENT
Appln. No.: 09/700,397

REMARKS

A computer readable form of the Sequence Listing has not previously been filed in this application. The paper copy of the Sequence Listing filed with the application was prepared using PatentIn version 2.0. However, to comply with the recent rule changes, a computer readable form of the Sequence Listing, and substitute paper copy, was prepared using PatentIn 3.0. The later version of PatentIn automatically produces a separate peptide sequence when a coding sequence is identified in a polynucleotide sequence. As a result, two identical peptide sequences were generated for some of the sequences upon use of version 3.0, and the replicates had to be deleted. In addition, the numbering of the sequences in the specification and claims had to be changed. Thus, the amendments to the specification and claims are necessitated by the generation of the computer readable format of the Sequence Listing using PatentIn 3.0.

No new matter has been introduced.

Entry and consideration of this Amendment is respectfully requested.

Respectfully submitted,



Drew Hissong
Registration No. 44,765

SUGHRUE, MION, ZINN,
MACPEAK & SEAS, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3213
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Date: January 5, 2001

09/700397

532 Rec'd PCT/TTO 14 NOV 2000

DESCRIPTION

NOVEL POLYPEPTIDES, cDNA ENCODING THE SAME, AND USE OF THEM

Technical Field

The present invention relates to a novel polypeptide, a cDNA encoding it and a pharmaceutical use of it.

Technical Background

Until now, when a man skilled in the art intends to obtain a particular polypeptide or a cDNA encoding it, he generally utilizes methods by confirming an aimed biological activity in a tissue or in a cell medium, isolating and purifying the polypeptide and then cloning a gene or methods by "expression-cloning" with the guidance of the said biological activity. However, physiologically active polypeptides in living body have often many kinds of activities. Therefore, it happens increasingly that after cloning a gene, the isolated gene is found to be identical to that encoding a polypeptide already known. In addition, some factors could be generated in only a very slight amount and/or under specific conditions and it makes difficult to isolate and to purify the factor and to confirm its biological activity.

Recent rapid developments in techniques for constructing cDNAs and sequencing techniques have made it possible to quickly sequence a large amount of cDNAs. By utilizing these techniques, a process, which comprises constructing cDNAs library using various cells or tissues, cloning the cDNA at random, identifying the nucleotide sequences thereof, expressing novel polypeptides encoded by them, is now in progress. Although this process is advantageous in that a gene can be cloned and information regarding its nucleotide sequence can be obtained without any biochemical or genetic analysis, the target gene can be discovered thereby only accidentally in many cases.

09/700397

532 Rec'd PCT/PTO 14 NOV 2000

Disclosure of the present invention

The present inventors have studied cloning method to isolate genes encoding proliferation and/or differentiation factors functioning in hematopoietic systems and immune systems. Focusing their attention on the fact that most of the secretory proteins such as proliferation and/or differentiation factors (for example various cytokines) and membrane proteins such as receptors thereof (hereafter these proteins will be referred to generally as secretory proteins and the like) have sequences called signal peptides in the N-termini, the inventors have conducted extensive studies on a process for efficiently and selectively cloning a gene encoding for a signal peptide. Finally, we have successfully developed a screening method for the signal peptides (signal sequence trap (SST)) by using mammalian cells (See Japanese Patent Application Kokai Hei 6-315380). We also developed yeast SST method on the same concept. By the method based on the same conception using yeast, (yeast SST method), genes including sequence encoding signal peptide can be identified more easily and efficiently (See USP No. 5, 536, 637).

The present inventors et al. have diligently performed certain investigation using the present invention in order to isolate novel factors (polypeptides) useful for treatment, diagnosis and/or study, particularly, secretory proteins containing secretory signal and membrane protein. From the result, the present inventors achieved to find novel secretory proteins and membrane proteins produced from cell lines and tissue, for example, human adult brain tissue, cell lines derived from human brain tissue and cell line derived from human bone marrow, and cDNAs encoding them, and then completed the present invention.

The present invention provides the cDNA sequences identified as clones OC001, OM237, OA004b which were isolated by the said yeast SST method using cDNA libraries prepared from human adult brain tissue and cell lines derived from human brain tissue (T98G, ATCC No. CRL-1690). Clones OC001, OM237, OA004b were full-length cDNA including full cDNA

sequences encoding membrane proteins (Each protein is represented as OC001, OM237, OA004b protein, respectively).

It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequences of OC001, OM237, OA004b of the present invention. In addition, the polypeptides of the present invention were expected to possess the transmembrane region by hydrophobicity analysis of the obtained amino acid sequences. From these results, it was proved that polypeptides OC001, OM237, OA004b of the present invention were new membrane proteins.

The present invention provides the cDNA sequence identified as clone OAF075b which was isolated by the said yeast SST method using cDNA libraries prepared from human bone marrow cell line HAS303 (human bone marrow cell line: provided from Prof. Keisuke Sotoyama, Dr. Makoto Aizawa, First Medicine, Tokyo Medical College. see J. Cell. Physiol. 148, 245-251, 1991 and Experimental Hematol. 22, 482-487, 1994). Clone OAF075b was a full-length cDNA including a full cDNA sequence encoding secretory protein (this protein is represented as OAF075b protein).

It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OAF075b of the present invention. In addition, the polypeptide of the present invention was expected to possess no transmembrane region by hydrophobicity analysis of the obtained amino acid sequence. From these results, it was proved that polypeptide of the present invention was a new secretory protein.

The present invention relates to

- (1) a polypeptide comprising an amino acid sequence of SEQ ID NOS. 1, 4,

6, 9 or 12,

- (2) a cDNA encoding the polypeptide described in (1),
- (3) a cDNA comprising a nucleotide sequence of SEQ ID NOS. 2, 5, 7, 10 or 13, and
- (4) a cDNA comprising a nucleotide sequence of SEQ ID NOS. 3, 8, 11 or 14.

Detailed Description of the present invention

The present invention relates to a substantially purified form of the polypeptide comprising the amino acid sequence shown in SEQ ID NOS. 1, 4, 6, 9 or 12, homologue thereof, fragment thereof or homologue of the fragment.

Further, the present invention relates to cDNAs encoding the above peptides. More particularly the invention is provided cDNAs comprising nucleotide sequence shown in SEQ ID NOS. 2, 5, 7, 10 or 13, and cDNA containing a fragment which is selectively hybridizing to the cDNA comprising nucleotide sequence shown in SEQ ID NOS. 2, 5, 7, 10, 13, 3, 8, 11 or 14. A said cDNA capable for hybridizing to the cDNA includes the contemporary sequence of the above sequence.

A polypeptide comprising amino acid sequence shown in SEQ ID NOS. 1, 4, 6, 9 or 12 in substantially purified form will generally comprise the polypeptide in a preparation in which more than 90%, e.g. 95%, 98% or 99% of the polypeptide in the preparation is that of the SEQ ID NOS. 1, 4, 6, 9 or 12.

A homologue of polypeptide comprising amino acid sequence shown in SEQ ID NOS. 1, 4, 6, 9 or 12 will be generally at least 70%, preferably at least 80 or 90% and more preferably at least 95% homologous to the polypeptide comprising the said amino acid sequence over a region of at least 20, preferably at least 30, for instance 40, 60 or 100 more contiguous amino acids. Such a polypeptide homologue will be referred to a polypeptide of the present invention.

Further, a fragment of polypeptide comprising amino acid sequence shown in SEQ ID NOS. 1, 4, 6, 9 or 12 or its homologues will be at least 10, preferably at least 15, for example 20, 25, 30, 40, 50 or 60 amino acids in length.

A cDNA capable of selectively hybridizing to the cDNA comprising nucleotide sequence shown in SEQ ID NOS. 2, 5, 7, 10, 13, 3, 8, 11 or 14 will be generally at least 70%, preferably at least 80 or 90% and more preferably at least 95% homologous to the cDNA comprising the said nucleotide sequence over a region of at least 20, preferably at least 30, for instance 40, 60 or 100 or more contiguous nucleotides. Such a cDNA will be referred to "a cDNA of the present invention".

Fragments of the cDNA comprising nucleotide sequence shown in SEQ ID NOS. 2, 5, 7, 10, 13, 3, 8, 11 or 14 will be at least 10, preferably at least 15, for example 20, 25, 30 or 40 nucleotides in length, and will be also referred to "a cDNA of the present invention" as used herein.

A further embodiment of the present invention provides replication and expression vectors carrying cDNA of the present invention. The vectors may be, for example, plasmid, virus or phage vectors provided with an origin of replication, optionally a promoter for the expression of the said cDNA and optionally a regulator of the promoter. The vector may contain one or more selectable marker genes, for example ampicillin resistance gene. The vector may be used in vitro, for example of the production of RNA corresponding to the cDNA, or used to transfect a host cell.

A further embodiment of the present invention provides host cells transformed with the vectors for the replication and expression of the cDNA of the present invention, including the cDNA comprising nucleotide sequence shown in SEQ ID NOS. 2, 5, 7, 10, 13, 3, 8, 11 or 14 or the open reading frame thereof. The cells will be chosen to be compatible with the vector and may for example be bacterial, yeast, insect cells or mammalian cells.

A further embodiment of the present invention provides a method of producing a polypeptide which comprises culturing host cells of the present

invention under conditions effective to express a polypeptide of the present invention. Preferably, in addition, such a method is carried out under conditions in which the polypeptide of the present invention is expressed and then produced from the host cells.

cDNA of the present invention may also be inserted into the vectors described above in an antisense orientation in order to prove for the production of antisense RNA. Such antisense RNA may be used in a method of controlling the levels of a polypeptide of the present invention in a cell.

The invention also provides monoclonal or polyclonal antibodies against a polypeptide of the present invention. The invention further provides a process for the production of monoclonal or polyclonal antibodies to the polypeptides of the present invention. Monoclonal antibodies may be prepared by common hybridoma technology using polypeptides of the present invention or fragments thereof, as an immunogen. Polyclonal antibodies may also be prepared by common means which comprise inoculating host animals, (for example a rat or a rabbit etc.), with polypeptides of the present invention and recovering immune serum.

The present invention also provides pharmaceutical compositions containing a polypeptide of the present invention, or an antibody thereof, in association with a pharmaceutically acceptable diluent and/or carrier.

The polypeptide of the present invention specified in (1) includes that which a part of their amino acid sequence is lacking (e.g., a polypeptide comprised of the only essential sequence for revealing a biological activity in an amino acid sequence shown in SEQ ID NO. 1), that which a part of their amino acid sequence is replaced by other amino acids (e. g., those replaced by an amino acid having a similar property) and that which other amino acids are added or inserted into a part of their amino acid sequence, as well as those comprising the amino acid sequence shown in SEQ ID NOS. 1, 4, 6, 9 or 12.

As known well, there are one to six kinds of codon as that encoding

one amino acid (for example, one kind of codon for Methionine (Met), and six kinds of codon for Leucine (Leu) are known). Accordingly, the nucleotide sequence of cDNA can be changed in order to encode the polypeptide having the same amino acid sequence.

The cDNA of the present invention, specified in (2) includes a group of every nucleotide sequence encoding polypeptides (1) shown in SEQ ID NOS. 1, 4, 6, 9 or 12. There is a probability that yield of a polypeptide is improved by changing a nucleotide sequence.

The cDNA specified in (3) is the embodiment of the cDNA shown in (2), and indicate the sequence of natural form.

The cDNA shown in (4) indicates the sequence of the cDNA specified in (3) with natural non-translational region.

cDNA carrying nucleotide sequence shown in SEQ ID NOS. 3, 8, 11 or 14 is prepared by the following method:

Brief description of Yeast SST method (see USP No. 5, 536, 637) is as follows.

Yeast such as *Saccharomyces cerevisiae* should secrete invertase into the medium in order to take sucrose or raffinose as a source of energy or carbon. (Invertase is an enzyme to cleave raffinose into sucrose and melibiose, sucrose into fructose and glucose). It is known that many known mammalian signal sequence make yeast secrete its invertase. From these knowledge, SST method was developed as a screening method to find novel signal peptide which make it possible can to secrete yeast invertase from mammalian cDNA library. SST method uses yeast growth on raffinose medium as a marker. Non-secretory type invertase gene SUC2 (GENBANK Accession No. V 01311) lacking initiation codon ATG was inserted to yeast expression vector to prepare yeast SST vector pSUC2. In this expression vector, ADH promoter, ADH terminator (both were derived from AAH5 plasmid (Gammerer, Methods in Enzymol. 101, 192-201, 1983)), 2 μ ori (as a yeast replication origin), TRP1 (as a yeast selective marker), ColE1 ori (as a E. Coli replication origin) and ampicillin resistance gene (as

a drug resistance marker) were inserted. Mammalian cDNA was inserted into the upstream of SUC2 gene to prepare yeast SST cDNA library. Yeast lacking secretory type invertase, was transformed with this library. If inserted mammalian cDNA encodes a signal peptide, yeast could survive in raffinose medium as a result of restoring secretion of invertase. Only to culture yeast colonies, prepare plasmids and determine the nucleotide sequence of the insert cDNAs, it is possible to identify novel signal peptide rapidly and easily.

Preparation of yeast SST cDNA library is as follows:

- (1) mRNA is isolated from the targeted cells, double-strand synthesis is performed by using random primer with certain restriction enzyme (enzyme I) recognition site,
- (2) obtained double-strand cDNA is ligated to adapter containing certain restriction endonuclease (enzyme II) recognition site, differ from enzyme I, digested with enzyme I and fractionated in a appropriate size,
- (3) obtained cDNA fragment is inserted into yeast expression vector on the upstream region of invertase gene which signal peptide is deleted and the library was transformed.

Detailed description of each step is as follows:

- (1) mRNA is isolated from mammalian organs and cell lines stimulate them with appropriate stimulator if necessary) by known methods (Molecular Cloning (Sambrook, J., Fritsch, E. F. and Maniatis, T., Cold Spring Harbor Laboratory Press, 1989) or Current Protocol in Molecular Biology (F. M. Ausubel et al, John Wiley & Sons, Inc) if not remark especially).

HAS303 (human bone marrow stroma cell line: provide from Professor Keisuke Sotoyama, Dr. Makoto Aizawa of First Medicine, Tokyo Medical College; see J. Cell. Physiol., 148, 245-251, 1991 and Experimental Hematol., 22, 482-487, 1994) or human glioblastoma cell line TG98G (ATCC No. CRL-1690) are chosen as a cell line. Human adult brain is chosen as a tissue source. Double-strand cDNA synthesis using random primer is performed by known methods.

Any sites may be used as restriction endonuclease recognition site I which is linked to adapter and restriction endonuclease recognition site II which is used in step (2), if both sites are different each other. Preferably, Xhol is used as enzyme I and EcoRI as enzyme II.

In step (2), cDNA is created blunt-ends with T4 DNA polymerase, ligated enzyme II adapter and digested with enzyme I. Fragment cDNA is analyzed with agarose-gel electrophoresis (AGE) and is selected cDNA fraction ranging in size from 300 to 800 bp. As mentioned above, any enzyme may be used as enzyme II if it is not same the enzyme I.

In step (3), cDNA fragment obtained in step (2) is inserted into yeast expression vector on the upstream region of invertase gene which signal peptide is deleted. E. Coli was transformed with the expression vector. Many vectors are known as yeast expression plasmid vector. For example, YEp24 is also functioned in E. Coli. Preferably pSUC2 as described above is used.

Many host E. Coli strains are known for transformation, preferably DH10B competent cell is used. Any known transformation method is available, preferably it is performed by electroporation method. Transformant is cultured by conventional methods to obtain cDNA library for yeast SST method.

However not every all of the clones do not contain cDNA fragment. Further all of the gene fragments do not encode unknown signal peptides. It is therefore necessary to screen a gene fragment encoding for an unknown signal peptide from the library.

Therefore, screening of fragments containing a sequence encoding an appropriate signal peptide is performed by transformation of the cDNA library into *Saccharomyces cerevisiae* (e. g. YT455 strain) which lack invertase (it may be prepared by known methods).

Transformation of yeast is performed by known methods, e. g. lithium acetate method. Transformant is cultured in a selective medium, then transferred to a medium containing raffinose as a carbon source.

Survival colonies are selected and then prepared plasmid. Survival colonies on a raffinose-medium indicates that some signal peptide of secretory protein was inserted to this clone.

As for isolated positive clones, the nucleotide sequence is determined. As to a cDNA encodes unknown protein, full-length clone may be isolated by using cDNA fragment as a probe and then determined to obtain full-length nucleotide sequence. These manipulation is performed by known methods.

Once the nucleotide sequences shown in SEQ ID NO. 2, 5, 7, 10 or 13 are determined partially or preferably fully, it is possible to obtain DNA encode mammalian protein itself, homologue or subset. cDNA library or mRNA derived from mammals was screened by PCR with any synthesized oligonucleotide primers or by hybridization with any fragment as a probe. It is possible to obtain DNA encodes other mammalian homologue protein from other mammalian cDNA or genome library.

If a cDNA obtained above contains a nucleotide sequence of cDNA fragment obtained by SST (or consensus sequence thereof), it will be thought that the cDNA encodes signal peptide. So it is clear that the cDNA will be full-length or almost full. (All signal peptides exist at N-termini of a protein and are encoded at 5'-termini of open reading frame of cDNA)

The confirmation may be carried out by Northern analysis with the said cDNA as a probe. It is thought that the cDNA is almost complete length, if length of the cDNA is almost the same length of the mRNA obtained in the hybridizing band.

Once the nucleotide sequences shown in SEQ ID NOS. 2, 5, 7, 10 or 13 are determined, DNAs of the invention are obtained by chemical synthesis, or by hybridization making use of nucleotide fragments which are chemically synthesized as a probe. Furthermore, DNAs of the invention are obtained in desired amount by transforming a vector that contains the DNA into a proper host, and culturing the transformant.

The polypeptides of the present invention may be prepared by:

(1) isolating and purifying from an organism or a cultured cell,
(2) chemically synthesizing, or
(3) using recombinant cDNA technology,
preferably, by the method described in (3) in an industrial production.

Examples of expression system (host-vector system) for producing a polypeptide by using recombinant cDNA technology are the expression systems of bacteria, yeast, insect cells and mammalian cells.

In the expression of the polypeptide, for example, in E. Coli, the expression vector is prepared by adding the initiation codon (ATG) to 5' end of a cDNA encoding mature peptide, connecting the cDNA thus obtained to the downstream of a proper promoter (e. g., trp promoter, lac promoter, λ PL promoter, T7 promoter etc.), and then inserting it into a vector (e. g., pBR322, pUC18, pUC19 etc.) which functions in an E. Coli strain.

Then, an E. Coli strain (e. g., E. Coli DH1 strain, E. Coli JM109 strain, E. Coli HB101 strain, etc.) which is transformed with the expression vector described above may be cultured in a appropriate medium to obtain the desired polypeptide. When a signal sequence of bacteria (e. g., signal sequence of pel B) is utilized, the desired polypeptide may be also released in periplasm. Furthermore, a fusion protein with other polypeptide may be also produced readily.

In the expression of the polypeptide, for example, in a mammalian cells, for example, the expression vector is prepared by inserting the cDNA encoding nucleotide shown in SEQ ID NOS. 3, 8, 11 or 14 into the downstream of a proper promoter (e. g., SV40 promoter, LTR promoter, metallothionein promoter etc.) in a proper vector (e. g., retrovirus vector, papilloma virus vector, vaccinia virus vector, SV40 vector, etc.). A proper mammalian cell (e. g., monkey COS-7 cell, Chinese hamster CHO cell, mouse L cell etc.) is transformed with the expression vector thus obtained, and then the transformant is cultured in a proper medium to express the aimed secretory protein and membrane protein of the present invention by the following method.

In case of secretory protein as for the present invention, the aimed polypeptide was expressed in the supernatant of the cells. In addition, fusion protein may be prepared by conjugating cDNA fragment encoding the other polypeptide, for example, Fc portion of antibody.

On the other hand, in case of membrane protein as for the present invention, the aimed polypeptide was expressed on the cell membrane. A cDNA encoding the nucleotide sequence of SEQ ID NOS. 2, 5, 7, 10 or 13 with deletion of extracellular region was inserted into the said vector, transfected into the an adequate mammalian cells to secret the aimed soluble polypeptide in the culture medium. In addition, fusion protein may be prepared by conjugating cDNA fragment encoding the said mutant with deletion of extracellular region and other polypeptide, for example, Fc portion of antibody.

The polypeptide available by the way described above can be isolated and purified by conventional biochemical method.

Industrial Applicability

It is considered that the polypeptide of the present invention and a cDNA which encodes the polypeptide will show one or more of the effects or biological activities (including those which relates to the assays cited below) The effects or biological activities described in relation to the polypeptide of the present invention are provided by administration or use of the polypeptide or by administration or use of a cDNA molecule which encodes the polypeptide (e. g., vector suitable for gene therapy or cDNA introduction).

[Cytokine activity and cell proliferation/differentiation activity]

The protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor dependent

cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a polypeptide of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines.

[Immune stimulating/suppressing activity]

The protein of the present invention may also exhibit immune stimulating or immune suppressing activity. The protein of the present invention may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e. g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral infection such as HIV as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases causes by viral, bacterial, fungal or other infection may be treatable using the polypeptide of the present invention, including infections by HIV, hepatitis viruses, herpes viruses, mycobacteria, leshmania, malaria and various fungal infections such as candida. Of course, in this regard, the protein of the present invention may also be useful where a boost to the immune system generally would be indicated, i. e., in the treatment of cancer.

The protein of the present invention may be useful in the treatment of allergic reactions and conditions, such as asthma or other respiratory problems. The protein of the present invention may also be useful in the treatment of the other conditions required to suppress the immuno system (for example, asthma or respiratory disease)

The protein of the present invention may also suppress chronic or acute inflammation, such as, for example, that associated with infection such as septic shock or systemic inflammatory response syndrome (SIRS), inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1 wherein the effect was

demonstrated by IL- 11.

[Hematopoiesis regulating activity]

The protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis. The said biological activities are concerned with the following all or some example(s). e. g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemia or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i. e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelosuppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either in-vitro or ex-vivo (i. e. in conjunction with bone marrow transplantation) as normal cells or genetically manipulated for gene therapy.

The suitable method of assay for proliferation and differentiation of various hematopoietic stem cell lines is described above.

The activity of the protein of the present invention may, among other

means, be measured by the following methods :

[Tissue generation/regeneration activity]

The protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, Ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair, and in the treatment of burns, incisions and ulcers.

The protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, may be applied to the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing the protein of the present invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

The protein of the present invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. The protein of the present invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. The protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, may be applied to the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans

and other animals. Such a preparation employing the protein inducing a tendon/Ligament-like tissue may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon Ligament cells or progenitors ex vivo for return in vivo to effect tissue repair. The compositions of the present invention may also be useful in the treatment of tendinitis, Carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue. i. e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, the protein of the present invention may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical

therapies may also be treatable using the polypeptide of the present invention.

It is expected that the protein of the present invention may also exhibit activity for generation of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the proliferation of cells comprising such tissues. Part of the desired effects may be by inhibition of fibrotic scarring to allow normal tissue to regenerate.

The protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

[Activin/Inhibin activity]

The protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, the protein of the present invention alone or in heterodimers with a member of the inhibin *a family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the present invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin-*b group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary (See USP 4, 798, 885). The protein of the present invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as

cows, sheep and pigs.

[Chemotactic/chemokinetic activity]

The protein of the present invention may have chemotactic or chemokinetic activity e. g., functioning as a chemokine, for mammalian cells, including, for example, monocytes, neutrophils, T-cells, mast cells, eosinophils and/or endothelial cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.

If a protein or peptide can stimulate, directly or indirectly, the directed orientation or movement of such cell population, it has chemotactic activity for a particular cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

[Hemostatic and thrombolytic activity]

The protein of the present invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the present invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom such as, for example, infarction or stroke.

[Receptor/ligand activity]

The protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including cellular adhesion molecules such as Selectins, Integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses. Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. The protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

[Other activity]

The protein of the present invention may also exhibit one or more of the following additional activities or effects: inhibiting growth of or killing the infecting agents including bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) body characteristics including height, weight, hair color, eye color, skin, other tissue pigmentation, or organ or body part size or shape such as, for example, breast augmentation or diminution etc.; effecting elimination of dietary fat, protein, carbohydrate; effecting behavioral characteristics including appetite, libido, stress, cognition (including cognitive disorders), depression and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases.

The protein with above activities, is suspected to have following functions by itself or interaction with its ligands or receptors or association

with other molecules. For example, proliferation or cell death of B cells, T cells and/or mast cells; specific induction by promotion of class switch of immunoglobulin genes; differentiation of B cells to antibody-forming cells; proliferation, differentiation, or cell death of precursors of granulocytes; proliferation, differentiation, or cell death of precursors of monocytes-macrophages; proliferation, or up regulation or cell death of neutrophils, monocytes-macrophages, eosinophils and/or basophils; proliferation, or cell death of precursors of megakaryocytes; proliferation, differentiation, or cell death of precursors of neutrophils; proliferation, differentiation, or cell death of precursors of T cells and B cells; promotion of production of erythrocytes; sustainment of proliferation of erythrocytes, neutrophils, eosinophils, basophils, monocytes-macrophages, mast cells, precursors of megakaryocyte; promotion of migration of neutrophils, monocytes-macrophages, B cells and/or T cells; proliferation or cell death of thymocytes; suppression of differentiation of adipocytes; proliferation or cell death of natural killer cells; proliferation or cell death of hematopoietic stem cells; suppression of proliferation of stem cells and each hematopoietic precursor cells; promotion of differentiation from mesenchymal stem cells to osteoblasts or chondrocytes, proliferation or cell death of mesenchymal stem cells, osteoblasts or chondrocytes and promotion of bone absorption by activation of osteoclasts and promotion of differentiation from monocytes to osteoclasts.

The polypeptide of the present invention is also suspected to function to nervous system, so expected to have functions below; differentiation to kinds of neurotransmitter-responsive neurons, survival or cell death of these cells; promotion of proliferation or cell death of glial cells; spread of neural dendrites; survival or cell death of gangriocytes; proliferation, promotion of differentiation, or cell death of astrocytes; proliferation, survival or cell death of peripheral neurons; proliferation or cell death of Schwann cells; proliferation, survival or cell death of motoneurons.

Furthermore, in the process of development of early embryonic, the polypeptide of the present invention is expected to promote or inhibit the

organogenesis of epidermis, brain, backbone, and nervous system by induction of ectoderm, that of notochord connective tissues (bone, muscle, tendon), hemocytes, heart, kidney, and genital organs by induction of mesoderm, and that of digestive apparatus (stomach, intestine, liver, pancreas), respiratory apparatus (lung, trachea) by induction of endoderm. In adult, also, this polypeptide is thought to proliferate or inhibit the above organs.

Therefore, the polypeptide of the present invention itself is expected to be used as an agent for the prevention or treatment of disease of progression or suppression of immune, nervous, or bone metabolic function, hypoplasia or overgrowth of hematopoietic cells: for example, inflammatory disease (rheumatism, ulcerative colitis, etc.), decrease of hematopoietic stem cells after bone marrow transplantation, decrease of leukocytes, platelets, B-cells, or T-cells after radiation exposure or chemotherapeutic dosage against cancer or leukemia, anemia, infectious disease, cancer, leukemia, AIDS, bone metabolic disease (osteoporosis etc.), various degenerative disease (Alzheimer's disease, multiple sclerosis, etc.), or nervous lesion.

In addition, since the polypeptide of the present invention is thought to induce the differentiation or growth of organs derived from ectoderm, mesoderm, and endoderm, this polypeptide is expected to be an agent for tissue repair (epidermis, bone, muscle, tendon, heart, kidney, stomach, intestine, liver, pancreas, lung, and trachea, etc.).

By using polyclonal or monoclonal antibodies against the polypeptide of the present invention, quantitation of the said polypeptide in the body can be performed. It can be used in the study of relationship between this polypeptide and disease or diagnosis of disease, and so on. Polyclonal and monoclonal antibodies can be prepared using this polypeptide or its fragment as an antigen by conventional methods.

Identification, purification or molecular cloning of known or unknown proteins which bind the polypeptide of the present invention (preferably polypeptide of extracellular domain) can be performed using the polypeptide

of the present invention by, for example, preparation of the affinity-column.

Identification of the downstream signal transmission molecules which interact with the polypeptide of the present invention in cytoplasma and molecular cloning of the gene can be performed by west-western method using the polypeptide of the present invention (preferably polypeptide of transmembrane region or intracellular domain), or by yeast two-hybrid system using the cDNA (preferably cDNA encoding transmembrane region or cytoplasmic domain of the polypeptide).

Agonists/antagonists of this receptor polypeptide and inhibitors between receptor and signal transduction molecules can be screened using the polypeptide of the present invention.

cDNAs of the present invention are useful not only the important and essential template for the production of the polypeptide of the present invention which is expected to be largely useful, but also be useful for diagnosis or therapy (for example, treatment of gene lacking, treatment to stop the expression of the polypeptide by antisense cDNA (mRNA)). Genomic cDNA may be isolated with the cDNA of the present invention, as a probe. As the same manner, a human gene encoding which can be highly homologous to the cDNA of the present invention, that is, which encodes a polypeptide highly homologous to the polypeptide of the present invention and a gene of animals excluding mouse which can be highly homologous to the cDNA of the present invention, also may be isolated.

[Application to Medicaments]

The polypeptide of the present invention or the antibody specific for the polypeptide of the present invention is administered systemically or topically and in general orally or parenterally, preferably parenterally, intravenously and intraventricularly, for preventing or treating the said diseases.

The doses to be administered depend upon age, body weight, symptom, desired therapeutic effect, route of administration, and duration of

the treatment etc. In human adults, one dose per person is generally between 100 μ g and 100 mg, by oral administration, up to several times per day, and between 10 μ g and 100 mg, by parental administration up to several times per day.

As mentioned above, the doses to be used depend upon various conditions. Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used.

The compounds of the present invention, may be administered as solid compositions, liquid compositions or other compositions for oral administration, as injections, liniments or suppositories etc. for parental administration.

Solid compositions for oral administration include compressed tablets, pills, capsules, dispersible powders, and granules. Capsules include soft or hard capsules.

In such compositions, one or more of the active compound(s) is or are admixed with at least one inert diluent (such as lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, magnesium metasilicate aluminate, etc.). The compositions may also comprise, as is normal practice, additional substances other than inert diluents: e. g. lubricating agents (such as magnesium stearate etc.), disintegrating agents (such as cellulose calcium glycolate, etc.), stabilizing agents (such as human serum albumin, lactose etc.), and assisting agents for dissolving (such as arginine, asparaginic acid etc.).

The tablets or pills may, if desired, be coated with a film of gastric or enteric materials (such as sugar, gelatin, hydroxypropyl cellulose or hydroxypropylmethyl cellulose phthalate, etc.), or be coated with more than two films. And then, coating may include containment within capsules of absorbable materials such as gelatin.

Liquid compositions for oral administration include pharmaceutically-acceptable emulsions, solutions, syrups and elixirs. In such compositions, one or more of the active compound(s) is or are contained in inert diluent(s)

commonly used (purified water, ethanol etc.). Besides inert diluents, such compositions may also comprise adjuvants (such as wetting agents, suspending agents, etc.), sweetening agents, flavoring agents, perfuming agents, and preserving agents.

Other compositions for oral administration include spray compositions which may be prepared by known methods and which comprise one or more of the active compound(s). Spray compositions may comprise additional substances other than inert diluents: e. g. stabilizing agents (sodium sulfite etc.), isotonic buffer (sodium chloride, sodium citrate, citric acid, etc.). For preparation of such spray compositions, for example, the method described in the United States Patent No. 2, 868, 691 or 3, 095, 355 (herein incorporated in their entireties by reference) may be used.

Injections for parental administration include sterile aqueous or non-aqueous solutions, suspensions and emulsions. In such compositions, one or more active compound(s) is or are admixed with at least one inert aqueous diluent(s) (distilled water for injection, physiological salt solution, etc.) or inert non-aqueous diluents(s) (propylene glycol, polyethylene glycol, olive oil, ethanol, POLYSOLBATE 80 (Trade mark) etc.).

Injections may comprise additional compound other than inert diluents: e. g. preserving agents, wetting agents, emulsifying agents, dispersing agents, stabilizing agent (such as human serum albumin, lactose, etc.), and assisting agents such as assisting agents for dissolving (arginine, asparaginic acid, etc.).

Best Mode carrying out the Invention

The invention is illustrated by the following examples relating to clone OC001 of the present invention, but not limit the invention.

Example 1: Preparation of Poly(A)⁺RNA

Total RNA was prepared from human placenta tissue by TRIzol reagent (Trade Mark, marketed from GIBCOBRL Co.). Poly(A)⁺RNA was

purified from the total RNA by mRNA Purification Kit (Trade name, marketed from Pharmacia Co.).

Example 2: Preparation of yeast SST cDNA library

Double strand cDNA was synthesized by Super Script Plasmid System for cDNA Synthesis and Plasmid Cloning (Trade name, marketed from GIBCOBRL Co.) with above poly(A)⁺RNA as template and random 9mer as primer which was containing Xhol site:

5'-CGATTGAATTCTAGACCTGCCTCGAGNNNNNNNN-3'
(SEQ ID NO. 15).

cDNA was ligated EcoRI adapter by DNA ligation kit ver. 2 (Trade name, marketed from Takara-Shuzo Co., this kit was used in all ligating steps hereafter) and digested by Xhol. cDNAs were separated by agarose-gel electrophoresis. 300~800 bp cDNAs were isolated and were ligated to EcoRI/NotI site of pSUC2 (see US Patent No. 5, 536, 637). E. Coli DH10B strains were transformed by pSUC2 with electroporation to obtain yeast SST cDNA library.

Example 3: Screening by SST method and determination of nucleotide sequence of SST positive clone

Plasmids of the said cDNA library were prepared. Yeast YTK12 strains were transformed by the plasmids with lithium acetate method (Current Protocols In Molecular Biology 13.7.1). The transformed yeast were plated on triptphan-free medium (CMD-Trp medium) for selection. The plate was incubated for 48 hour at 30 °C. Replica of the colony (transformant) which was obtained by Accutran Replica Plater (Trade name, marketed from Schleicher & Schuell Co.) were placed onto YPR plate containing raffinose for carbon source, and the plate was incubated for 14 days at 30°C. After 3 days, each colony appeared was streaked on YPR plate again. The plates were incubated for 48 hours at 30°C. Single colony was inoculated to YPD medium and was incubated for 48 hours at 30°C.

Then plasmids were prepared. Insert cDNA was amplified by PCR with two kind primers which exist end side of cloning site on pSUC2 (sense strand primers were biotinylated). Biotinylated single strand of cDNAs were purified with Dynabeads (Trade name, marketed from DYNAL Co.) and the nucleotide sequences were determined. Sequencing was performed by Dye Terminator Cycle Sequencing Ready Reaction with DNA Sequencing kit (Trade name, marketed from Applied Biosystems Inc.) and sequence was determined by DNA sequencer 373 (Applied Biosystems Inc.) (All sequencing hereafter was carried out with this method).

We tried to carry out cloning of full-length cDNA which was proved to be new one according to the homology search for the obtained nucleotide sequences and deduced amino acid sequences in data base.

Example 4: Cloning of a full-length cDNA and determination of nucleotide sequence of clone OC001

A full-length cDNA was cloned using Marathon cDNA Amplification Kit (Trade name, marketed from Clontech Co.) according to 3' RACE (Rapid Amplification of cDNA End) method. I. e., poly (A)⁺RNA in human adult brain tissue 27mer primer OC001-F1:

5'-GTCCTTCAGCAAAACAGTGGATTAAA-3' (SEQ ID NO. 16)
containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. A cDNA which was amplified with clone OC001 specifically, was separated with agarose-gel electrophoresis, ligated to pT7 Blue-2 T-Vector (Trade name, marketed from Novagen Co) and transfected into E. Coli DH5 α to prepare the plasmid. Nucleotide sequences of 5'-end were determined, and the existence of nucleotide sequence OC001 SST cDNA was confirmed. Nucleotide sequence of full-length OC001 SST cDNA was determined and then sequence shown in SEQ ID NO. 3 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide

sequence shown in SEQ ID NOS. 1, 2, 4 and 5, respectively, were obtained.

It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OC001 of the present invention. In addition, the polypeptide of the present invention was expected to possess the transmembrane region at C-terminal and to be GPI anchor type by hydrophobisity analysis of the obtained amino acid sequence. From these results, it was proved that polypeptide of the present invention was new membrane protein. Further, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OC001 (region of 12th~344th amino acid in SEQ ID NO. 1) and neurotrimin [Rattus norvegicus] (region of 9th~344th amino acid of Genbank Accession U16845) and opioid-binding cell adhesion molecule [Homo sapiens] (region of 9th~345th amino acid of Genbank Accession L34774). Based on these homologies, clone OC001 and nervous cell adhesion molecule family including neurotrimin and opioid-binding cell adhesion molecule were expected to share at least some activity.

Example 5: Cloning of a full-length cDNA and determination of nucleotide sequence of clone OM237

In Example relating to clone OM237 of the present invention, the same procedure as in Example of OC001 was used except for the following points.

A full-length cDNA was cloned by the same procedure as OC001 using Marathon cDNA Amplification Kit (Trade name, marketed from Clontech Co.) according to 3'RACE. A double-strand cDNA was prepaed from RNA derived from each clone, i. e., poly(A)⁺RNA of human adult brain tissue. 27mer primer OM237-F1:

5'-CCAGAAAGCACAGCCCTGATTCTGCGT-3' (SEQ ID NO. 17)
containing the deduced initiation ATG codon region based on the information

of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. A cDNA which was amplified with clone OM237 specifically, was recloned by the same method as OC001 to determine full necleotide sequence and obtain the sequence shown in SEQ ID NO. 8. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 6 and 7, respectively, were obtained.

It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OM237 of the present invention. In addition, the polypeptide of the present invention was expected to possess the transmembrane region by hydrophobisity analysis of the obtained amino acid sequence. From these results, it was proved that polypeptide of the present invention was new membrane protein.

Example 6: Cloning of a full-length cDNA and determination of nucleotide sequence of clone OA004b

In Example relating to clone OA004b of the present invention, the same procedure as in Example of OC001 was used except for the following points.

[preparation of poly(A)⁺RNA]

Total RNA was prepared from human glioblastoma cell line T98G (ATCC No. CRL-1690) by TRIzol reagent (Trade Mark, marketed from GIBCOBRL Co.). Poly(A)⁺RNA was purified from total RNA by mRNA Purification Kit (Trade name, marketed from Pharmacia Co.).

[Cloning of a full-length cDNA and detemination of amino acid sequnce]

A full-length cDNA was cloned by GENETRAPPER cDNA Positive Selection System (GIBCOBRL Co.). First, dT-primed cDNA library was

prepared using plasmid pSPORT1 (GIBCOBRL Co.) as a vector from poly(A)⁺RNA of human glioblastoma cell line T98G by Super Script Plasmid System for cDNA Synthesis and Plasmid Cloning (Trade name, marketed from GIBCOBRL Co.). After preparing 27mer biotinylated primer OA004-F1:

5'-biotin-ATGCACATCTTCAAGCATGCTCAG-3' (SEQ ID NO. 18), based on the information of nucleotide sequence obtained by SST, plasmid hybridized specifically with the biotinylated primer were recovered from the cDNA library according to the method of Gene Trapper Kit and then transfected into E. Coli DH10B. Colony hybridization with OA004 SST cDNA which was labeled with ³²P-dCTP, as a probe, was performed by using Random Primer DNA Labeling kit (Trade name, marketed from Takara-Shuzo Co.) according to known method to isolate the positive clone and to prepare the plasmid. Full Nucleotide sequences was determined, and then sequence shown in SEQ ID NO. 11, which was named as OA004b, was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 9 and 10, respectively, were obtained.

It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OA004b of the present invention. In addition, the polypeptide of the present invention was expected to possess the transmembrane region by hydrophobicity analysis of the obtained amino acid sequence. From these results, it was proved that polypeptide of the present invention was new membrane protein. However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OA004b (region of 171st~311st amino acid in SEQ ID NO. 9) and Hypothetical 52.8kD protein [Caenorhabditis elegans] (region of 299th~453rd amino acid of Swiss Prot Accession YJ95_CAEEL), and between

OA004b (region of 194th~277th amino acid in SEQ ID NO. 9) and presenilin-2 [Homo sapiens] (region of 340th~416th amino acid of Genbank Accession A56993). Based on these homologies, clone OA004b and presenilin family were expected to share at least some activity.

Example 7: Cloning of a full-length cDNA and determination of nucleotide sequence of clone OAF075b

In Example relating to clone OAF075b of the present invention, the same procedure as in Example of OC001 was used except for the following points.

[Preparation of poly(A)⁺RNA]

Total RNA was prepared from human bone marrow stroma cell line HAS303 (provided from Prof. Keisuke Sotoyama, Dr. Makoto Aizawa, First Medicine, Tokyo Medical College) by TRIzol reagent (Trade Mark, marketed from GIBCOBRL Co.). Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit (Trade name, marketed from Pharmacia Co.).

[Cloning of a full-length cDNA and determination of amino acid sequence]

A full-length cDNA was cloned by the same procedure as OC001 using Marathon cDNA Amplification Kit (Trade name, marketed from Clontech Co.) according to 3'RACE. A double-strand cDNA was prepared from RNA derived from each clone, i. e., poly(A)⁺RNA of HAS303. 27mer primer OAF075-F1:

5'-CCCCGGGGACATGAGGTGGACTGT-3' (SEQ ID NO. 19)
containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. A cDNA which was amplified with clone OAF075B specifically, was recloned by the same method as OC001 to determine full nucleotide sequence and obtain the sequence shown in SEQ ID NO. 14, which was named as OAF075b. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 12 and 13, respectively, were

obtained.

It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OAF075b of the present invention.

In addition, the polypeptides of the present invention was expected to possess no transmembrane region by hydrophobisity analysis of the obtained amino acid sequences. From these results, it was proved that polypeptide of the present invention was new secretory protein. Further, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OAF075b (region of 1st~359th amino acid in SEQ ID NO. 12) and preprocarboxypeptidase A2 [Homo sapiens] (region of 1st~355th amino acid of Genbank Accession U19977). Based on these homologies, clone OAF075b and preprocarboxypeptidase A2 [Homo sapiens] were expected to share at least some activity.

Claim

1. A substantially purified form of the polypeptide comprising the amino acid sequence shown in SEQ ID NOS. 1, 4, 6, 9 or 12, homologue thereof, fragment thereof or homologue of the fragment.
2. A polypeptide according to claim 1 comprising the amino acid sequence shown in SEQ ID NOS. 1, 4, 6, 9 or 12.
3. A cDNA encoding the polypeptide according to claim 1.
4. A cDNA according to claim 3 comprising the nucleotide sequence shown in SEQ ID NOS. 2, 5, 7, 10 or 13, or a fragment cDNA selectively hybridized to the cDNA.
5. A cDNA according to claim 3 comprising the nucleotide sequence shown in SEQ ID NOS. 3, 8, 11 or 14, or a fragment cDNA selectively hybridized to the cDNA.
6. A replication or expression vector carrying the cDNA according to claims 3 to 5.
7. A host cell transformed with the replication or expression vector according to claim 6.
8. A method for producing the polypeptide according to claim 1 or 2 which comprises culturing a host cell according to claim 7 under a condition effective to express the polypeptide according to claim 1 or 2.
9. A monoclonal or polyclonal antibody against the polypeptide according to claim 1 or 2.

10. A pharmaceutical composition containing the polypeptide according to claim 1 or 2 or the antibody according to claim 9, in association with pharmaceutically acceptable diluent and/or carrier.

Abstract

A new human polypeptide, a cDNA encoding the same and a pharmaceutical use of it.

The polypeptides of the present invention possess hematopoiesis regulating activity, tissue generation/regeneration activity, activin/inhibin activity, chemotactic/chemokinetic activity, hemostatic and thrombolytic activity, and receptor/ligand activity, therefore, they are expected to be useful for prevention and/or treatment of various diseases.

RECEIVED
JULY 10 1997
U.S. PATENT AND TRADEMARK OFFICE

09/700397

532 Rec'd PCT/PTO 14 NOV 2000

SEQUENCE LISTING

<110> Ono Pharmaceutical Co., Ltd.

<120> Novel Polypeptides, cDNA coding these polypeptides and Use thereof

<130> ONF-2975PCT

<141> 1999-05-13

<150> JP 10-131815

<151> 1998-05-14

<160> 19

<170> PatentIn Ver. 2.0

<210> 1

<211> 344

<212> PRT

<213> Homo sapiens

<400> 1

Met Lys Thr Ile Gln Pro Lys Met His Asn Ser Ile Ser Trp Ala Ile

-25

-20

-15

Phe Thr Gly Leu Ala Ala Leu Cys Leu Phe Gln Gly Val Pro Val Arg
-10 -5 -1 1

Ser Gly Asp Ala Thr Phe Pro Lys Ala Met Asp Asn Val Thr Val Arg
5 10 15 20

Gln Gly Glu Ser Ala Thr Leu Arg Cys Thr Ile Asp Asn Arg Val Thr
25 30 35

Arg Val Ala Trp Leu Asn Arg Ser Thr Ile Leu Tyr Ala Gly Asn Asp
40 45 50

Lys Trp Cys Leu Asp Pro Arg Val Val Leu Leu Ser Asn Thr Gln Thr
55 60 65

Gln Tyr Ser Ile Glu Ile Gln Asn Val Asp Val Tyr Asp Glu Gly Pro
70 75 80

Tyr Thr Cys Ser Val Gln Thr Asp Asn His Pro Lys Thr Ser Arg Val
85 90 95 100

His Leu Ile Val Gln Val Ser Pro Lys Ile Val Glu Ile Ser Ser Asp
105 110 115

Ile Ser Ile Asn Glu Gly Asn Asn Ile Ser Leu Thr Cys Ile Ala Thr
120 125 130

Gly Arg Pro Glu Pro Thr Val Thr Trp Arg His Ile Ser Pro Lys Ala
135 140 145

Val Gly Phe Val Ser Glu Asp Glu Tyr Leu Glu Ile Gln Gly Ile Thr
150 155 160

Arg Glu Gln Ser Gly Asp Tyr Glu Cys Ser Ala Ser Asn Asp Val Ala
165 170 175 180

Ala Pro Val Val Arg Arg Val Lys Val Thr Val Asn Tyr Pro Pro Tyr
185 190 195
Ile Ser Glu Ala Lys Gly Thr Gly Val Pro Val Gly Gln Lys Gly Thr
200 205 210
Leu Gln Cys Glu Ala Ser Ala Val Pro Ser Ala Glu Phe Gln Trp Tyr
215 220 225
Lys Asp Asp Lys Arg Leu Ile Glu Gly Lys Lys Gly Val Lys Val Glu
230 235 240
Asn Arg Pro Phe Leu Ser Lys Leu Ile Phe Phe Asn Val Ser Glu His
245 250 255 260
Asp Tyr Gly Asn Tyr Thr Cys Val Ala Ser Asn Lys Leu Gly His Thr
265 270 275
Asn Ala Ser Ile Met Leu Phe Gly Pro Gly Ala Val Ser Glu Val Ser
280 285 290
Asn Gly Thr Ser Arg Arg Ala Gly Cys Val Trp Leu Leu Pro Leu Leu
295 300 305
Val Leu His Leu Leu Lys Phe
310 315

<210> 2

<211> 1032

<212> DNA

<213> Homo sapiens

<400> 2

atgaaaacca tccagccaaa aatgcacaat tctatctttt gggcaatctt cacggggctg 60
gtcgctctgt gtctcttcca aggagtcccc gtgcgcagcg gagatgccac cttccccaaa 120
gctatggaca acgtgacggt ccggcagggg gagagcgcca ccctcaggtg cactattgac 180
aaccgggtca cccgggtggc ctggctaaac cgcatcacca tcctctatgc tggaatgac 240
aagtggtgcc tggatcctcg cgtggtcctt ctgagcaaca cccaaacgca gtacagcatac 300
gagatccaga acgtggatgt gtatgacgag gcccttaca cctgctcggt gcagacagac 360
aaccacccaa agacctctag ggtccaccc atttgcaag tatctccaa aattgttagag 420
atttcttcag atatctccat taatgaaggg aacaatatta gcctcacctg catagcaact 480
ggtagaccag agcctacggt tacttgaga cacatctctc ccaaagcggt tggctttgtg 540
agtgaagacg aatacttgga aattcaggc atcacccggg agcagtcagg ggactacgag 600
tgcagtgcct ccaatgacgt ggccgcggcc gtggtacgga gagtaaaggt caccgtgaac 660
tatccaccat acatttcaga agccaagggt acaggtgtcc ccgtggaca aaaggggaca 720
ctgcagtgtg aagcctcagc agtccccta gcagaattcc agtggtacaa ggatgacaaa 780
agactgattg aaggaaagaa aggggtgaaa gtggaaaaca gacctttctt ctcaaaactc 840
atcttcttca atgtctctga acatgactat gggactaca ttgcgtggc ctccaacaag 900
ctggccaca ccaatgccag catcatgcta tttggtccag gcgcgcgtcag cgaggtgagc 960
aacggcacgt cgaggaggc aggctgcgtc tggctgctgc ctcttctggc cttgcacactg 1020
cttctcaaat tt 1032

<210> 3

<211> 1693

<212> DNA

<213> Homo sapiens

<220>

<223> Clone OC001 derived from human brain

<220>

<221> CDS

<222> (130)..(1161)

<220>

<221> sig_peptide

<222> (130)..(213)

<220>

<221> mat_peptide

<222> (214)..(1161)

<400> 3

gtccttcagc aaaacagtgg atttaaatct cttgcacaa gttgagagc aacacaatct 60

atcaggaaag aaagaaagaa aaaaaaccga acctgacaaa aaagaagaaa aagaagaaga 120

aaaaaaaaatc atg aaa acc atc cag cca aaa atg cac aat tct atc tct tgg 171

Met Lys Thr Ile Gln Pro Lys Met His Asn Ser Ile Ser Trp

-25

-20

-15

gca atc ttc acg ggg ctg gct ctg tgt ctc ttc caa gga gtg ccc 219
 Ala Ile Phe Thr Gly Leu Ala Ala Leu Cys Leu Phe Gln Gly Val Pro
 -10 -5 -1 1
 gtg cgc agc gga gat gcc acc ttc ccc aaa gct atg gac aac gtg acg 267
 Val Arg Ser Gly Asp Ala Thr Phe Pro Lys Ala Met Asp Asn Val Thr
 5 10 15
 gtc cgg cag ggg gag agc gcc acc ctc agg tgc act att gac aac cgg 315
 Val Arg Gln Gly Glu Ser Ala Thr Leu Arg Cys Thr Ile Asp Asn Arg
 20 25 30
 gtc acc cgg gtg gcc tgg cta aac cgc agc acc atc ctc tat gct ggg 363
 Val Thr Arg Val Ala Trp Leu Asn Arg Ser Thr Ile Leu Tyr Ala Gly
 35 40 45 50
 aat gac aag tgg tgc ctg gat cct cgc gtg gtc ctt ctg agc aac acc 411
 Asn Asp Lys Trp Cys Leu Asp Pro Arg Val Val Leu Leu Ser Asn Thr
 55 60 65
 caa acg cag tac agc atc gag atc cag aac gtg gat gtg tat gac gag 459
 Gln Thr Gln Tyr Ser Ile Glu Ile Gln Asn Val Asp Val Tyr Asp Glu
 70 75 80
 ggc cct tac acc tgc tcg gtg cag aca gac aac cac cca aag acc tct 507
 Gly Pro Tyr Thr Cys Ser Val Gln Thr Asp Asn His Pro Lys Thr Ser
 85 90 95
 agg gtc cac ctc att gtg caa gta tct ccc aaa att gta gag att tct 555
 Arg Val His Leu Ile Val Gln Val Ser Pro Lys Ile Val Glu Ile Ser
 100 105 110

tca	gat	atc	tcc	att	aat	gaa	ggg	aac	aat	att	agc	ctc	acc	tgc	ata	603
Ser	Asp	Ile	Ser	Ile	Asn	Glu	Gly	Asn	Asn	Ile	Ser	Leu	Thr	Cys	Ile	
115			120					125				130				
gca	act	ggt	aga	cca	gag	cct	acg	gtt	act	tgg	aga	cac	atc	tct	ccc	651
Ala	Thr	Gly	Arg	Pro	Glu	Pro	Thr	Val	Thr	Trp	Arg	His	Ile	Ser	Pro	
			135					140				145				
aaa	gcg	gtt	ggc	ttt	gtg	agt	gaa	gac	gaa	tac	ttg	gaa	att	cag	ggc	699
Lys	Ala	Val	Gly	Phe	Val	Ser	Glu	Asp	Glu	Tyr	Leu	Glu	Ile	Gln	Gly	
			150			155				160						
atc	acc	cgg	gag	cag	tca	ggg	gac	tac	gag	tgc	agt	gcc	tcc	aat	gac	747
Ile	Thr	Arg	Glu	Gln	Ser	Gly	Asp	Tyr	Glu	Cys	Ser	Ala	Ser	Asn	Asp	
			165			170				175						
gtg	gcc	gcg	ccc	gtg	gta	cgg	aga	gta	aag	gtc	acc	gtg	aac	tat	cca	795
Val	Ala	Ala	Pro	Val	Val	Arg	Arg	Val	Lys	Val	Thr	Val	Asn	Tyr	Pro	
			180			185				190						
cca	tac	att	tca	gaa	gcc	aag	ggt	aca	ggt	gtc	ccc	gtg	gga	caa	aag	843
Pro	Tyr	Ile	Ser	Glu	Ala	Lys	Gly	Thr	Gly	Val	Pro	Val	Gly	Gln	Lys	
195			200					205				210				
ggg	aca	ctg	cag	tgt	gaa	gcc	tca	gca	gtc	ccc	tca	gca	gaa	ttc	cag	891
Gly	Thr	Leu	Gln	Cys	Glu	Ala	Ser	Ala	Val	Pro	Ser	Ala	Glu	Phe	Gln	
			215			220				225						
tgg	tac	aag	gat	gac	aaa	aga	ctg	att	gaa	gga	aag	aaa	ggg	gtg	aaa	939
Trp	Tyr	Lys	Asp	Asp	Lys	Arg	Leu	Ile	Glu	Gly	Lys	Lys	Gly	Val	Lys	
			230			235				240						

gtg gaa aac aga cct ttc ctc tca aaa ctc atc ttc ttc aat gtc tct 987
 Val Glu Asn Arg Pro Phe Leu Ser Lys Leu Ile Phe Phe Asn Val Ser
 245 250 255
 gaa cat gac tat ggg aac tac act tgc gtg gcc tcc aac aag ctg ggc 1035
 Glu His Asp Tyr Gly Asn Tyr Thr Cys Val Ala Ser Asn Lys Leu Gly
 260 265 270
 cac acc aat gcc agc atc atg cta ttt ggt cca ggc gcc gtc agc gag 1083
 His Thr Asn Ala Ser Ile Met Leu Phe Gly Pro Gly Ala Val Ser Glu
 275 280 285 290
 gtg agc aac ggc acg tcg agg gca ggc tgc gtc tgg ctg ctg cct 1131
 Val Ser Asn Gly Thr Ser Arg Arg Ala Gly Cys Val Trp Leu Leu Pro
 295 300 305
 ctt ctg gtc ttg cac ctg ctt ctc aaa ttt tgatgtgagt gccacttccc 1181
 Leu Leu Val Leu His Leu Leu Lys Phe
 310 315
 cacccggaa aggctgccgc caccaccacc accaacacaa cagcaatggc aacaccgaca 1241
 gcaaccaatc agatatatac aaatgaaatt agaagaaaaca cagcctcatg ggacagaaaat 1301
 ttgagggagg ggaacaaaga atactttggg gggaaaaaaag tttaaaaaaa gaaattgaaa 1361
 attgccttgc agatatttag gtacaatgga gttttttttt cccaaacggg aagaacacag 1421
 cacacccggc ttggacccac tgcaagctgc atcgtgcaac ctcttggtg ccagtgtggg 1481
 caagggctca gcctctctgc ccacagagtg cccccacgtg gaacattctg gagctggcca 1541
 tcccaaattc aatcagtcca tagagacgaa cagaatgaga cttccggcc caagcgtggc 1601
 gctgcggca ctgtggtaga ctgtgccacc acggcgtgtg ttgtgaaacg tggaaataaaa 1661
 agagcaaaaaa aaaaaaaaaa aaaaaaaaaa aa 1693

<210> 4

<211> 313

<212> PRT

<213> Homo sapiens

<400> 4

Arg Ser Gly Asp Ala Thr Phe Pro Lys Ala Met Asp Asn Val Thr Val

1 5 10 15

Arg Gln Gly Glu Ser Ala Thr Leu Arg Cys Thr Ile Asp Asn Arg Val

20 25 30

Thr Arg Val Ala Trp Leu Asn Arg Ser Thr Ile Leu Tyr Ala Gly Asn

35 40 45

Asp Lys Trp Cys Leu Asp Pro Arg Val Val Leu Leu Ser Asn Thr Gln

50 55 60

Thr Gln Tyr Ser Ile Glu Ile Gln Asn Val Asp Val Tyr Asp Glu Gly

65 70 75 80

Pro Tyr Thr Cys Ser Val Gln Thr Asp Asn His Pro Lys Thr Ser Arg

85 90 95

Val His Leu Ile Val Gln Val Ser Pro Lys Ile Val Glu Ile Ser Ser

100 105 110

Asp Ile Ser Ile Asn Glu Gly Asn Asn Ile Ser Leu Thr Cys Ile Ala

115 120 125

Thr Gly Arg Pro Glu Pro Thr Val Thr Trp Arg His Ile Ser Pro Lys
130 135 140
Ala Val Gly Phe Val Ser Glu Asp Glu Tyr Leu Glu Ile Gln Gly Ile
145 150 155 160
Thr Arg Glu Gln Ser Gly Asp Tyr Glu Cys Ser Ala Ser Asn Asp Val
165 170 175
Ala Ala Pro Val Val Arg Arg Val Lys Val Thr Val Asn Tyr Pro Pro
180 185 190
Tyr Ile Ser Glu Ala Lys Gly Thr Gly Val Pro Val Gly Gln Lys Gly
195 200 205
Thr Leu Gln Cys Glu Ala Ser Ala Val Pro Ser Ala Glu Phe Gln Trp
210 215 220
Tyr Lys Asp Asp Lys Arg Leu Ile Glu Gly Lys Lys Gly Val Lys Val
225 230 235 240
Glu Asn Arg Pro Phe Leu Ser Lys Leu Ile Phe Phe Asn Val Ser Glu
245 250 255
His Asp Tyr Gly Asn Tyr Thr Cys Val Ala Ser Asn Lys Leu Gly His
260 265 270
Thr Asn Ala Ser Ile Met Leu Phe Gly Pro Gly Ala Val Ser Glu Val
275 280 285
Ser Asn Gly Thr Ser Arg Arg Ala Gly Cys Val Trp Leu Leu Pro Leu
290 295 300
Leu Val Leu His Leu Leu Lys Phe
305 310

<210> 5

<211> 939

<212> DNA

<213> Homo sapiens

<400> 5

cgcagcggag atgccaccc cccaaagct atggacaacg tgacggtccg gcaggggag 60
agcgccaccc tcaggtgcac tattgacaac cgggtcaccc gggtggcctg gctaaaccgc 120
agcaccatcc tctatgctgg gaatgacaag tggtgccctgg atcctcgcgt ggtccttctg 180
agcaacacccc aaacgcagta cagcatcgag atccagaacg tggatgtgta tgacgaggc 240
ccttacacct gctcggtgca gacagacaac cacccaaaga cctctagggt ccacccatt 300
gtgcaagtat ctccccaaat tgttagagatt tcttcagata tctccattaa tgaagggAAC 360
aatattagcc tcacctgcat agcaactggt agaccagagc ctacggttac ttggagacac 420
atctctccca aagcggttgg ctttgtgagt gaagacgaat acttggaaat tcagggcatc 480
accgggagc agtcagggga ctacgagtgc agtgcctcca atgacgtggc cgcccccgtg 540
gtacggagag taaaggtcac cgtgaactat ccaccatACA tttcagaAGC caagggtaca 600
ggtgtccccg tgggacaaaa ggggacactg cagtgtgaag cctcagcagt cccctcagca 660
gaattccagt ggtacaagga tgacaaaaga ctgattgaag gaaagaaagg ggtgaaagtg 720
gaaaacagac ctttcctctc aaaactcatc ttcttcaatg tctctgaaca tgactatggg 780
aactacactt gcgtggcctc caacaagctg ggccacacca atgccagcat catgtatTTT 840
ggtccaggcg ccgtcagcga ggtgagcaac ggcacgtcga ggagggcagg ctgcgtctgg 900
ctgctgcctc ttctggctt gcacctgctt ctcaaattt 939

<210> 6

<211> 478

<212> PRT

<213> Homo sapiens

<400> 6

Met Phe Lys Phe His Gln Met Lys His Ile Phe Glu Ile Leu Asp Lys

1 5 10 15

Met Arg Cys Leu Arg Lys Arg Ser Thr Val Ser Phe Leu Gly Val Leu

20 25 30

Val Ile Phe Leu Leu Phe Met Asn Leu Tyr Ile Glu Asp Ser Tyr Val

35 40 45

Leu Glu Gly Asp Lys Gln Leu Ile Arg Glu Thr Ser Thr His Gln Leu

50 55 60

Asn Ser Glu Arg Tyr Val His Thr Phe Lys Asp Leu Ser Asn Phe Ser

65 70 75 80

Gly Ala Ile Asn Val Thr Tyr Arg Tyr Leu Ala Ala Thr Pro Leu Gln

85 90 95

Arg Lys Arg Tyr Leu Thr Ile Gly Leu Ser Ser Val Lys Arg Lys Lys

100 105 110

Gly Asn Tyr Leu Leu Glu Thr Ile Lys Ser Ile Phe Glu Gln Ser Ser

115 120 125

Tyr Glu Glu Leu Lys Glu Ile Ser Val Val Ile His Leu Ala Asp Phe
130 135 140

Asn Ser Ser Trp Arg Asp Ala Met Val Gln Asp Ile Thr Gln Lys Phe
145 150 155 160

Ala His His Ile Ile Ala Gly Arg Leu Met Val Ile His Ala Pro Glu
165 170 175

Glu Tyr Tyr Pro Ile Leu Asp Gly Leu Lys Arg Asn Tyr Asn Asp Pro
180 185 190

Glu Asp Arg Val Lys Phe Arg Ser Lys Gln Asn Val Asp Tyr Thr Phe
195 200 205

Leu Leu Asn Phe Cys Ala Asn Thr Ser Asp Tyr Tyr Val Met Leu Glu
210 215 220

Asp Asp Val Arg Cys Ser Lys Asn Phe Leu Thr Ala Ile Lys Lys Val
225 230 235 240

Ile Ala Ser Leu Glu Gly Thr Tyr Trp Val Thr Leu Glu Phe Ser Lys
245 250 255

Leu Gly Tyr Ile Gly Lys Leu Tyr His Ser His Asp Leu Pro Arg Leu
260 265 270

Ala His Phe Leu Leu Met Phe Tyr Gln Glu Met Pro Cys Asp Trp Leu
275 280 285

Leu Thr His Phe Arg Gly Leu Leu Ala Gln Lys Asn Val Ile Arg Phe
290 295 300

Lys Pro Ser Leu Phe Gln His Met Gly Tyr Tyr Ser Ser Tyr Lys Gly
305 310 315 320

Thr Glu Asn Lys Leu Lys Asp Asp Asp Phe Glu Glu Glu Ser Phe Asp
325 330 335
Ile Pro Asp Asn Pro Pro Ala Ser Leu Tyr Thr Asn Met Asn Val Phe
340 345 350
Glu Asn Tyr Glu Ala Ser Lys Ala Tyr Ser Ser Val Asp Glu Tyr Phe
355 360 365
Trp Gly Lys Pro Pro Ser Thr Gly Asp Val Phe Val Ile Val Phe Glu
370 375 380
Asn Pro Ile Ile Ile Lys Lys Ile Lys Val Asn Thr Gly Thr Glu Asp
385 390 395 400
Arg Gln Asn Asp Ile Leu His His Gly Ala Leu Asp Val Gly Glu Asn
405 410 415
Val Met Pro Ser Lys Gln Arg Gly Gln Cys Ser Thr Tyr Leu Arg Leu
420 425 430
Gly Glu Phe Lys Asn Gly Asn Phe Glu Met Ser Gly Val Asn Gln Lys
435 440 445
Ile Pro Phe Asp Ile His Cys Met Arg Ile Tyr Val Thr Lys Thr Gln
450 455 460
Lys Glu Trp Leu Ile Ile Arg Ser Ile Ser Ile Trp Thr Ser
465 470 475

<210> 7

<211> 1434

<212> DNA

<213> Homo sapiens

<400> 7

atgtttaaat ttcatcaaataaaacatatt tttgaaataac ttgataaaaat gagatgcctg 60
agaaaacgtt ctacagtgtc attcttgga gttcttgtca ttttctcct ttttatgaac 120
ttgtacattg aagatagcta tggtaatggaa ggagacaaac aacttataag ggaaacatcc 180
acacatcaac tgaattcaga acgctatgtt catactttca aggatttac taatttctca 240
ggagccataa atgtcaccta tcgctaccta gctgccacac ctttacaaag aaagcggtat 300
cttacaattt gactttcttc agtaaaggcga aaaaaaggaa actatttact tgagacaatt 360
aagtcaattt ttgagcaatc cagctatgaa gagctgaagg aaatttcaat ggtgattcac 420
ctagcagact ttaatttcttc ctggcgtgat gccatggtcc aggatattac acagaaattt 480
gcgcaccata ttattgcagg aagattaatg gttatacatg ctccagagga gtattaccca 540
atccttagatg gccttaaaag aaattacaat gatccagaag atagagtcaa atttcgttcc 600
aagcaaaatg tagattatac tttctgctt aattttgtg ccaatacttc agactattat 660
gtaatgctt aagatgatgt tcgatgttca aaaaatttct taactgccat caagaaagtc 720
attgcattttcc tagaaggaac ttactggta actcttgaat tctctaagct tggctacatt 780
ggtaaactct atcattctca tgatctccca cgtttggccc attttttatt aatgtttat 840
caagaaatgc ctgtgattt gctattgact catttccgtg gtctgttggc tcagaaaaat 900
gtgatccgtt ttaaaccatc tcttttcag cacatggctt attattcatc atacaaaggg 960
acggagaata agctgaagga tggatgtttt gaagaggagt catttgacat tcctgataac 1020
ccccctgcaa gtctgtacac caacatgaat gtgtttgaaa attatgaagc aagcaaggct 1080
tacagtagtg ttgatgagta cttttgggg aaaccaccc caacaggaga tggatgtt 1140
attgtatggaaaatccat tataataaaa aaaattaaag taaatactgg aacagaagat 1200

cggc当地atg atatttgca tcatggagcc ctagatgtt gggaaaacgt tatgc当地tagc 1260
aaac当地aaagg gacaatgttc tacttactta agactaggag aattcaaaaa tggaaacttt 1320
gaaatgtcag gtgt当地aatca aaaaattcca tttgatatac attgtatgag gatataatgtc 1380
acc当地aaacac aaaaggaatg gctaatttattt aggagtatta gc当地ttggac ttct 1434

<210> 8

<211> 2131

<212> DNA

<213> Homo sapiens

<220>

<223> Clone OM237 derived from human brain

<220>

<221> CDS

<222> (114)..(1547)

<400> 8

ccagaaaagca cagccctgat tctgcgtgag aaaggctatc tctacagaaaa ctaaaaacggt 60
atcaacggtt tctgtacagc acagattatg acagegtctt tcttaagaag aga atg 116

Met

1

ttt aaa ttt cat caa atg aaa cat att ttt gaa ata ctt gat aaa atg 164

Phe Lys Phe His Gln Met Lys His Ile Phe Glu Ile Leu Asp Lys Met
 5 10 15
 aga tgc ctg aga aaa cgt tct aca gtg tca ttc ttg gga gtt ctt gtc 212
 Arg Cys Leu Arg Lys Arg Ser Thr Val Ser Phe Leu Gly Val Leu Val
 20 25 30
 att ttt ctc ctt ttt atg aac ttg tac att gaa gat agc tat gtt ctg 260
 Ile Phe Leu Leu Phe Met Asn Leu Tyr Ile Glu Asp Ser Tyr Val Leu
 35 40 45
 gaa gga gac aaa caa ctt ata agg gaa aca tcc aca cat caa ctg aat 308
 Glu Gly Asp Lys Gln Leu Ile Arg Glu Thr Ser Thr His Gln Leu Asn
 50 55 60 65
 tca gaa cgc tat gtt cat act ttc aag gat tta tct aat ttc tca gga 356
 Ser Glu Arg Tyr Val His Thr Phe Lys Asp Leu Ser Asn Phe Ser Gly
 70 75 80
 gcc ata aat gtc acc tat cgc tac cta gct gcc aca cct tta caa aga 404
 Ala Ile Asn Val Thr Tyr Arg Tyr Leu Ala Ala Thr Pro Leu Gln Arg
 85 90 95
 aag cgg tat ctt aca att gga ctt tct tca gta aag cga aaa aaa gga 452
 Lys Arg Tyr Leu Thr Ile Gly Leu Ser Ser Val Lys Arg Lys Gly
 100 105 110
 aac tat tta ctt gag aca att aag tca att ttt gag caa tcc agc tat 500
 Asn Tyr Leu Leu Glu Thr Ile Lys Ser Ile Phe Glu Gln Ser Ser Tyr
 115 120 125
 gaa gag ctg aag gaa att tca gtg gtg att cac cta gca gac ttt aat 548

Glu Glu Leu Lys Glu Ile Ser Val Val Ile His Leu Ala Asp Phe Asn
130 135 140 145
tct tcc tgg cgt gat gcc atg gtc cag gat att aca cag aaa ttt gcg 596
Ser Ser Trp Arg Asp Ala Met Val Gln Asp Ile Thr Gln Lys Phe Ala
150 155 160
cac cat att att gca gga aga tta atg gtt ata cat gct cca gag gag 644
His His Ile Ile Ala Gly Arg Leu Met Val Ile His Ala Pro Glu Glu
165 170 175
tat tac cca atc cta gat ggc ctt aaa aga aat tac aat gat cca gaa 692
Tyr Tyr Pro Ile Leu Asp Gly Leu Lys Arg Asn Tyr Asn Asp Pro Glu
180 185 190
gat aga gtc aaa ttt cgt tcc aag caa aat gta gat tat act ttt ctg 740
Asp Arg Val Lys Phe Arg Ser Lys Gln Asn Val Asp Tyr Thr Phe Leu
195 200 205
ctt aat ttt tgt gcc aat act tca gac tat tat gta atg ctt gaa gat 788
Leu Asn Phe Cys Ala Asn Thr Ser Asp Tyr Tyr Val Met Leu Glu Asp
210 215 220 225
gat gtt cga tgt tca aaa aat ttc tta act gcc atc aag aaa gtc att 836
Asp Val Arg Cys Ser Lys Asn Phe Leu Thr Ala Ile Lys Lys Val Ile
230 235 240
gca tcc cta gaa gga act tac tgg gta act ctt gaa ttc tct aag ctt 884
Ala Ser Leu Glu Gly Thr Tyr Trp Val Thr Leu Glu Phe Ser Lys Leu
245 250 255
ggc tac att ggt aaa ctc tat cat tct cat gat ctc cca cgt ttg gcc 932

Gly Tyr Ile Gly Lys Leu Tyr His Ser His Asp Leu Pro Arg Leu Ala
 260 265 270
 cat ttt tta tta atg ttt tat caa gaa atg cct tgt gat tgg cta ttg 980
 His Phe Leu Leu Met Phe Tyr Gln Glu Met Pro Cys Asp Trp Leu Leu
 275 280 285
 act cat ttc cgt ggt ctg ttg gct cag aaa aat gtg atc cgt ttt aaa 1028
 Thr His Phe Arg Gly Leu Leu Ala Gln Lys Asn Val Ile Arg Phe Lys
 290 295 300 305
 cca tct ctc ttt cag cac atg ggc tat tat tca tca tac aaa ggg acg 1076
 Pro Ser Leu Phe Gln His Met Gly Tyr Tyr Ser Ser Tyr Lys Gly Thr
 310 315 320
 gag aat aag ctg aag gat gat ttt gaa gag gag tca ttt gac att 1124
 Glu Asn Lys Leu Lys Asp Asp Asp Phe Glu Glu Ser Phe Asp Ile
 325 330 335
 cct gat aac ccc cct gca agt ctg tac acc aac atg aat gtg ttt gaa 1172
 Pro Asp Asn Pro Pro Ala Ser Leu Tyr Thr Asn Met Asn Val Phe Glu
 340 345 350
 aat tat gaa gca agc aag gct tac agt agt gtt gat gag tac ttt tgg 1220
 Asn Tyr Glu Ala Ser Lys Ala Tyr Ser Ser Val Asp Glu Tyr Phe Trp
 355 360 365
 ggg aaa cca cct tca aca gga gat gtt ttt gtg att gta ttt gaa aat 1268
 Gly Lys Pro Pro Ser Thr Gly Asp Val Phe Val Ile Val Phe Glu Asn
 370 375 380 385
 cca att ata ata aaa aaa att aaa gta aat act gga aca gaa gat cgg 1316

Pro Ile Ile Ile Lys Lys Ile Lys Val Asn Thr Gly Thr Glu Asp Arg
390 395 400
caa aat gat att ttg cat cat gga gcc cta gat gtt ggg gaa aac gtt 1364
Gln Asn Asp Ile Leu His His Gly Ala Leu Asp Val Gly Glu Asn Val
405 410 415
atg cct agc aaa caa agg gga caa tgt tct act tac tta aga cta gga 1412
Met Pro Ser Lys Gln Arg Gly Gln Cys Ser Thr Tyr Leu Arg Leu Gly
420 425 430
gaa ttc aaa aat gga aac ttt gaa atg tca ggt gta aat caa aaa att 1460
Glu Phe Lys Asn Gly Asn Phe Glu Met Ser Gly Val Asn Gln Lys Ile
435 440 445
cca ttt gat ata cat tgt atg agg ata tat gtc acc aaa aca caa aag 1508
Pro Phe Asp Ile His Cys Met Arg Ile Tyr Val Thr Lys Thr Gln Lys
450 455 460 465
gaa tgg cta att att agg agt att agc att tgg act tct tagccaatta 1557
Glu Trp Leu Ile Ile Arg Ser Ile Ser Ile Trp Thr Ser
470 475
aatcagtatg ttcatgtttctt gaagcagttc ttccgttttttgc acctttgtct 1617
tttggaggga aagcaatggta tggttatgt taaaagaaac attaattaca ttggcagttt 1677
tcatttatac atttgtgaca taattttact cttaatacac acttgttattt attttaacgt 1737
ctgaagttga atatcagtct atagctaattttttt ctactttcat ttatattttt aaatgttctt 1797
agttttaaaa ttcaactga ttgtcgaaag ggtaatatga aagattttaa atgaaaaaaa 1857
tttgttgat gatgattttt gaaaaatagt caccaactgt atataacttcc tcaagaactg 1917
ataattcatt atatcatcag atagctttta ttaagcatct gtggaaatat acagttgggt 1977

ggaatgataa tctggtttat tttttctgta aacttaagtt tccgttgact tctgtacatc 2037
tacaatgaat acctcctcat agaagtggtg tctttacata atttttgtg taggtgacac 2097
tatggaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 2131

<210> 9

<211> 335

<212> PRT

<213> Homo sapiens

<400> 9

Met Asp Ser Ala Leu Ser Asp Pro His Asn Gly Ser Ala Glu Ala Gly

1 5 10 15

Gly Pro Thr Asn Ser Thr Thr Arg Pro Pro Ser Thr Pro Glu Gly Ile

20 25 30

Ala Leu Ala Tyr Gly Ser Leu Leu Leu Met Ala Leu Leu Pro Ile Phe

35 40 45

Phe Gly Ala Leu Arg Ser Val Arg Cys Ala Arg Gly Lys Asn Ala Ser

50 55 60

Asp Met Pro Glu Thr Ile Thr Ser Arg Asp Ala Ala Arg Phe Pro Ile

65 70 75 80

Ile Ala Ser Cys Thr Leu Leu Gly Leu Tyr Leu Phe Phe Lys Ile Phe

85 90 95

Ser Gln Glu Tyr Ile Asn Leu Leu Leu Ser Met Tyr Phe Phe Val Leu

100 105 110

Gly Ile Leu Ala Leu Ser His Thr Ile Ser Pro Phe Met Asn Lys Phe

115 120 125

Phe Pro Ala Ser Phe Pro Asn Arg Gln Tyr Gln Leu Leu Phe Thr Gln

130 135 140

Gly Ser Gly Glu Asn Lys Glu Glu Ile Ile Asn Tyr Glu Phe Asp Thr

145 150 155 160

Lys Asp Leu Val Cys Leu Gly Leu Ser Ser Ile Val Gly Val Trp Tyr

165 170 175

Leu Leu Arg Lys Val Phe Gly Thr Asn Val Met Val Thr Val Ala Lys

180 185 190

Ser Phe Glu Ala Pro Ile Lys Leu Val Phe Pro Gln Asp Leu Leu Glu

195 200 205

Lys Gly Leu Glu Ala Asn Asn Phe Ala Met Leu Gly Leu Gly Asp Val

210 215 220

Val Ile Pro Gly Ile Phe Ile Ala Leu Leu Arg Phe Asp Ile Ser

225 230 235 240

Leu Lys Lys Asn Thr His Thr Tyr Phe Tyr Thr Ser Phe Ala Ala Tyr

245 250 255

Ile Phe Gly Leu Gly Leu Thr Ile Phe Ile Met His Ile Phe Lys His

260 265 270

Ala Gln Pro Ala Leu Leu Tyr Leu Val Pro Ala Cys Ile Gly Phe Pro

275 280 285

Val Leu Val Ala Leu Ala Lys Gly Glu Val Thr Glu Met Phe Ser Tyr

290 295 300
Glu Glu Ser Asn Pro Lys Asp Pro Ala Ala Val Thr Glu Ser Lys Glu
305 310 315 320
Gly Thr Glu Ala Ser Ala Ser Lys Gly Leu Glu Lys Lys Glu Lys
325 330 335

<210> 10

<211> 1005

<212> DNA

<213> Homo sapiens

<400> 10

atggactcg ccctcagcga tccgcataac ggcagtgcg aggaggcgg ccccaccaac 60
agcaactacgc ggccgccttc cacgccc gag ggcatgcgc tggectacgg cagcctcctg 120
ctcatggcgc tgctgccat cttttcg gc cctgcgc ct cgta cgtg cggc 180
aagaatgctt cagacatgcc taaaacaatc accagccggg atgcgc cccg cttcccatc 240
atcgccagct gcacactttt gggctctac ctctttca aaatattctc ccaggagttac 300
atcaacctcc tgctgtccat gtatttcttc gtgctggaa tcctggccct gtccccacacc 360
atcagccct tcatgaataa gtttttcca gccagcttca caaatcgaca gtaccagctg 420
ctcttcacac agggttctgg gaaaaacaag gaagagatca tcaattatga atttgacacc 480
aaggacctgg tgtgcctggg cctgagcagc atcggtggcg tctggcacct gctgaggaag 540
gtatttggca ccaatgtgat ggtgacagtg gccaagtcct tcgaggcacc aataaaattg 600
gtgtttcccc aggatctgct ggagaaaggc ctcgaagcaa acaactttgc catgctggga 660

cttggagatg tcgtcattcc agggatcttc attgcattgc tgctgcgtt tgacatcagc 720
ttgaagaaga ataccacac ctacttctac accagcttg cagcctacat cttcgccctg 780
ggccttacca tcttcattcat gcacatcttc aagcatgctc agcctgcct cctatacctg 840
gtccccgcct gcatcggtt tcctgtcctg gtggcgctgg ccaagggaga agtgacagag 900
atgttcagtt atgaggagtc aaatcctaag gatccagcgg cagtgacaga atccaaagag 960
ggaacagagg catcagcatc gaaggggctg gagaagaaaag agaaa 1005

<210> 11

<211> 1486

<212> DNA

<213> Homo sapiens

<220>

<223> Clone 0A004b derived from T98G cell

<220>

<221> CDS

<222> (117)..(1121)

<400> 11

cacgtcactt cctgtgcct tagggaaacg tggcttccc tgcagagccg gtgtctccgc 60
ctgcgtccct gctgcagcaa ccggagctgg agtcggatcc cgaacgcacc ctcgcc atg 119

Met

gac tcg gcc ctc agc gat ccg cat aac ggc agt gcc gag gca ggc ggc 167
 Asp Ser Ala Leu Ser Asp Pro His Asn Gly Ser Ala Glu Ala Gly Gly
 5 10 15

ccc acc aac agc act acg cg^g cc^g ct^c tcc ac^g ccc gag ggc atc gc^g 215
 Pro Thr Asn Ser Thr Thr Arg Pro Pro Ser Thr Pro Glu Gly Ile Ala
 20 25 30

ctg gcc tac gg^c agc ctc ctg ctc at^g gc^g ctg ctg ccc atc tt^c tt^c 263
 Leu Ala Tyr Gly Ser Leu Leu Leu Met Ala Leu Leu Pro Ile Phe Phe
 35 40 45

gg^c gc^c ctg cg^c tc^c gt^a cg^c tg^c gc^c gg^c aag aat gt^c tc^a ga^c 311
 Gly Ala Leu Arg Ser Val Arg Cys Ala Arg Gly Lys Asn Ala Ser Asp
 50 55 60 65

at^g cc^t ga^a ac^a at^c ac^c ag^c cg^g ga^t gc^c gc^c tt^c cc^c at^c at^c 359
 Met Pro Glu Thr Ile Thr Ser Arg Asp Ala Ala Arg Phe Pro Ile Ile
 70 75 80

gc^c ag^c tg^c ac^a ct^c tt^g gg^g ct^c ta^c ct^c tt^t tt^c aa^a at^a tt^c tc^c 407
 Ala Ser Cys Thr Leu Leu Gly Leu Tyr Leu Phe Phe Lys Ile Phe Ser
 85 90 95

ca^g ga^g ta^c aac ct^c ct^g ct^g tcc at^g ta^t tt^c tt^c gt^g ct^g gg^a 455
 Gln Glu Tyr Ile Asn Leu Leu Ser Met Tyr Phe Phe Val Leu Gly
 100 105 110

at^c ct^g gc^c ct^g tc^c ca^c ac^c at^c ag^c cc^c tt^c at^g aat aag tt^t tt^t 503
 Ile Leu Ala Leu Ser His Thr Ile Ser Pro Phe Met Asn Lys Phe Phe

115	120	125	
cca gcc agc ttt cca aat cga cag tac cag ctg ctc ttc aca cag ggt 551			
Pro Ala Ser Phe Pro Asn Arg Gln Tyr Gln Leu Leu Phe Thr Gln Gly			
130	135	140	145
tct ggg gaa aac aag gaa gag atc atc aat tat gaa ttt gac acc aag 599			
Ser Gly Glu Asn Lys Glu Glu Ile Ile Asn Tyr Glu Phe Asp Thr Lys			
150	155	160	
gac ctg gtg tgc ctg ggc ctg agc agc atc gtt ggc gtc tgg tac ctg 647			
Asp Leu Val Cys Leu Gly Leu Ser Ser Ile Val Gly Val Trp Tyr Leu			
165	170	175	
ctg agg aag gta ttt ggc acc aat gtg atg gtg aca gtg gcc aag tcc 695			
Leu Arg Lys Val Phe Gly Thr Asn Val Met Val Thr Val Ala Lys Ser			
180	185	190	
ttc gag gca cca ata aaa ttg gtg ttt ccc cag gat ctg ctg gag aaa 743			
Phe Glu Ala Pro Ile Lys Leu Val Phe Pro Gln Asp Leu Leu Glu Lys			
195	200	205	
ggc ctc gaa gca aac aac ttt gcc atg ctg gga ctt gga gat gtc gtc 791			
Gly Leu Glu Ala Asn Asn Phe Ala Met Leu Gly Leu Gly Asp Val Val			
210	215	220	225
att cca ggg atc ttc att gcc ttg ctg ctg cgc ttt gac atc agc ttg 839			
Ile Pro Gly Ile Phe Ile Ala Leu Leu Leu Arg Phe Asp Ile Ser Leu			
230	235	240	
aag aag aat acc cac acc tac ttc tac acc agc ttt gca gcc tac atc 887			
Lys Lys Asn Thr His Thr Tyr Phe Tyr Thr Ser Phe Ala Ala Tyr Ile			

245	250	255	
ttc ggc ctg ggc ctt acc atc ttc atc atg cac atc ttc aag cat gct 935			
Phe Gly Leu Gly Leu Thr Ile Phe Ile Met His Ile Phe Lys His Ala			
260	265	270	
cag cct gcc ctc cta tac ctg gtc ccc gcc tgc atc ggt ttt cct gtc 983			
Gln Pro Ala Leu Leu Tyr Leu Val Pro Ala Cys Ile Gly Phe Pro Val			
275	280	285	
ctg gtg gcg ctg gcc aag gga gaa gtg aca gag atg ttc agt tat gag 1031			
Leu Val Ala Leu Ala Lys Gly Glu Val Thr Glu Met Phe Ser Tyr Glu			
290	295	300	305
gag tca aat cct aag gat cca gcg gca gtg aca gaa tcc aaa gag gga 1079			
Glu Ser Asn Pro Lys Asp Pro Ala Ala Val Thr Glu Ser Lys Glu Gly			
310	315	320	
aca gag gca tca gca tcg aag ggg ctg gag aag aaa gag aaa 1121			
Thr Glu Ala Ser Ala Ser Lys Gly Leu Glu Lys Lys Glu Lys			
325	330	335	
tgatgcggct ggtccccgag cctctcaggcc ccagaccaga cagatggggg ctggggccac 1181			
acaggcgtgc accggtagag ggcacaggag gccaaggggca gctccaggac agggcagggg 1241			
gcagcaggat acctccagcc aggcctctgt ggcctctgtt tccttctccc tttcttggcc 1301			
ctcctctgct cctccccaca ccctgcaggc aaaagaaaacc cccagttcc cccctccccg 1361			
ggagccaggt gggaaaagtg ggtgtgattt tttagattttg tattgtggac tgattttgcc 1421			
tcacattaaa aactcatccc atggccaggc cgggccactg tgctcctgaa aaaaaaaaaaa 1481			
aaaaaa 1486			

<210> 12

<211> 360

<212> PRT

<213> Homo sapiens

<400> 12

Met Arg Trp Ile Leu Phe Ile Gly Ala Leu Ile Gly Ser Ser Ile Cys
-15 -10 -5 -1
Gly Gln Glu Lys Phe Phe Gly Asp Gln Val Phe Arg Ile Asn Val Arg
1 5 10 15
Asn Gly Asp Glu Ile Ser Lys Leu Ser Gln Leu Val Asn Ser Asn Asn
20 25 30
Leu Lys Leu Asn Phe Trp Lys Ser Pro Ser Ser Phe Asn Arg Pro Val
35 40 45
Asp Val Leu Val Pro Ser Val Ser Leu Gln Ala Phe Lys Ser Phe Leu
50 55 60
Arg Ser Gln Gly Leu Glu Tyr Ala Val Thr Ile Glu Asp Leu Gln Ala
65 70 75 80
Leu Leu Asp Asn Glu Asp Asp Glu Met Gln His Asn Glu Gly Gln Glu
85 90 95
Arg Ser Ser Asn Asn Phe Asn Tyr Gly Ala Tyr His Ser Leu Glu Ala
100 105 110
Ile Tyr His Glu Met Asp Asn Ile Ala Ala Asp Phe Pro Asp Leu Ala

115 120 125
Arg Arg Val Lys Ile Gly His Ser Phe Glu Asn Arg Pro Met Tyr Val
130 135 140
Leu Lys Phe Ser Thr Gly Lys Gly Val Arg Arg Pro Ala Val Trp Leu
145 150 155 160
Asn Ala Gly Ile His Ser Arg Glu Trp Ile Ser Gln Ala Thr Ala Ile
165 170 175
Trp Thr Ala Arg Lys Ile Val Ser Asp Tyr Gln Arg Asp Pro Ala Ile
180 185 190
Thr Ser Ile Leu Glu Lys Met Asp Ile Phe Leu Leu Pro Val Ala Asn
195 200 205
Pro Asp Gly Tyr Val Tyr Thr Gln Thr Gln Asn Arg Leu Trp Arg Lys
210 215 220
Thr Arg Ser Arg Asn Pro Gly Ser Ser Cys Ile Gly Ala Asp Pro Asn
225 230 235 240
Arg Ser Trp Asn Ala Ser Phe Ala Gly Lys Gly Ala Ser Asp Asn Pro
245 250 255
Cys Ser Glu Val Tyr His Gly Pro His Ala Asn Ser Glu Val Glu Val
260 265 270
Lys Ser Val Val Asp Phe Ile Gln Lys His Gly Asn Phe Lys Cys Phe
275 280 285
Ile Asp Leu His Ser Tyr Ser Gln Leu Leu Met Tyr Pro Tyr Gly Tyr
290 295 300
Ser Val Lys Lys Ala Pro Asp Ala Glu Glu Leu Asp Lys Val Ala Arg

305 310 315 320

Leu Ala Ala Lys Ala Leu Ala Ser Val Ser Gly Thr Glu Tyr Gln Val

325 330 335

Gly Pro Thr Cys Thr Thr Val Leu

340

<210> 13

<211> 1080

<212> DNA

<213> Homo sapiens

<400> 13

atgaggtgga tactttcat tggggccctt attgggtcca gcatctgtgg ccaagaaaaa 60
ttttttgggg accaagtttt taggattaaat gtcagaaaatg gagacgagat cagcaaattg 120
agtcaactag tgaattcaaa caacttgaag ctcaatttct ggaaatctcc ctcctccttc 180
aatcggcctg tggatgtcct ggtcccatct gtcagtctgc aggcatttaa atccttcctg 240
agatcccagg gcttagagta cgcaatgtaca attgaggacc tgcaggccct tttagacaat 300
gaagatgatg aaatgcaaca caatgaaggg caagaacgga gcagtaataa cttcaactac 360
ggggcttacc attccctgga agctattac cacgagatgg acaacattgc cgcaagactt 420
cctgacctgg cgaggagggt gaagattgga cattcggttg aaaaccggcc gatgtatgta 480
ctgaagttca gcactggaa aggcggtgagg cggccggccg tttggctgaa tgcaggcatc 540
cattcccgag agtggatctc ccaggccact gcaatctgga cggcaaggaa gattgtatct 600
gattaccaga gggatccagc tatcacctcc atcttggaga aaatggatat tttcttggttg 660

cctgtggcca atcctgatgg atatgtgtat actcaaactc aaaaccgatt atggaggaag 720
acgcggtccc gaaatcctgg aagctcctgc attggtgctg acccaaatacg aagctggaac 780
gctagtttg cagggaaagg agccagcgac aacccttgct ccgaagtgtac ccatggaccc 840
cacGCCAATT CGGAAGTGGG GGTGAAATCA GTGGTAGATT TCAATCCAAAA ACATGGGAAT 900
ttcaagtgct tcacgacct gcacagctac tcgcagctgc tgcagttcc atatgggtac 960
tcagtcaaaa aggccccaga tgccgaggaa ctgcacaagg tggcgaggct tgcggccaaa 1020
gctctggctt ctgtgtcggtt cactgagttac caagtgggtc ccacctgcac cactgtctta 1080

<210> 14

<211> 3156

<212> DNA

<213> Homo sapiens

<220>

<223> Clone 0AF075b derived from human bone marrow stroma cell HAS303

<220>

<221> CDS

<222> (11)..(1090)

<220>

<221> sig_peptide

<222> (11)..(58)

<220>

<221> mat_peptide

<222> (59)..(1090)

<400> 14

ccccggggac atg agg tgg ata ctg ttc att ggg gcc ctt att ggg tcc 49

Met Arg Trp Ile Leu Phe Ile Gly Ala Leu Ile Gly Ser

-15 -10 -5

agc atc tgt ggc caa gaa aaa ttt ttt ggg gac caa gtt ttt agg att 97

Ser Ile Cys Gly Gln Glu Lys Phe Phe Gly Asp Gln Val Phe Arg Ile

-1 1 5 10

aat gtc aga aat gga gac gag atc agc aaa ttg agt caa cta gtg aat 145

Asn Val Arg Asn Gly Asp Glu Ile Ser Lys Leu Ser Gln Leu Val Asn

15 20 25

tca aac aac ttg aag ctc aat ttc tgg aaa tct ccc tcc tcc ttc aat 193

Ser Asn Asn Leu Lys Leu Asn Phe Trp Lys Ser Pro Ser Ser Phe Asn

30 35 40 45

cgg cct gtg gat gtc ctg gtc cca tct gtc agt ctg cag gca ttt aaa 241

Arg Pro Val Asp Val Leu Val Pro Ser Val Ser Leu Gln Ala Phe Lys

50 55 60

tcc ttc ctg aga tcc cag ggc tta gag tac gca gtg aca att gag gac 289

Ser Phe Leu Arg Ser Gln Gly Leu Glu Tyr Ala Val Thr Ile Glu Asp

65 70 75

ctg cag gcc ctt tta gac aat gaa gat gat gaa atg caa cac aat gaa	337		
Leu Gln Ala Leu Leu Asp Asn Glu Asp Asp Glu Met Gln His Asn Glu			
80	85	90	
ggg caa gaa cg ^g agc agt aat aac ttc aac tac ggg gct tac cat tcc	385		
Gly Gln Glu Arg Ser Ser Asn Asn Phe Asn Tyr Gly Ala Tyr His Ser			
95	100	105	
ctg gaa gct att tac cac gag atg gac aac att gcc gca gac ttt cct	433		
Leu Glu Ala Ile Tyr His Glu Met Asp Asn Ile Ala Ala Asp Phe Pro			
110	115	120	125
gac ctg gc ^g agg agg gtg aag att gga cat tc ^g ttt gaa aac cg ^g cc ^g	481		
Asp Leu Ala Arg Arg Val Lys Ile Gly His Ser Phe Glu Asn Arg Pro			
130	135	140	
atg tat gta ctg aag ttc agc act ggg aaa ggc gtg agg cg ^g cc ^g gcc	529		
Met Tyr Val Leu Lys Phe Ser Thr Gly Lys Gly Val Arg Arg Pro Ala			
145	150	155	
gtt tgg ctg aat gca ggc atc cat tcc cga gag tgg atc tcc cag gcc	577		
Val Trp Leu Asn Ala Gly Ile His Ser Arg Glu Trp Ile Ser Gln Ala			
160	165	170	
act gca atc tgg acg gca agg aag att gta tct gat tac cag agg gat	625		
Thr Ala Ile Trp Thr Ala Arg Lys Ile Val Ser Asp Tyr Gln Arg Asp			
175	180	185	
cca gct atc acc tcc atc ttg gag aaa atg gat att ttc ttg ttg cct	673		
Pro Ala Ile Thr Ser Ile Leu Glu Lys Met Asp Ile Phe Leu Leu Pro			
190	195	200	205

gtg gcc aat cct gat gga tat gtg tat act caa act caa aac cga tta 721
Val Ala Asn Pro Asp Gly Tyr Val Tyr Thr Gln Thr Gln Asn Arg Leu
210 215 220

tgg agg aag acg cg^g tcc cga aat cct gga agc tcc tgc att ggt gct 769
Trp Arg Lys Thr Arg Ser Arg Asn Pro Gly Ser Ser Cys Ile Gly Ala
225 230 235

gac cca aat aga agc tgg aac gct agt ttt gca gga aag gga gcc agc 817
Asp Pro Asn Arg Ser Trp Asn Ala Ser Phe Ala Gly Lys Gly Ala Ser
240 245 250

gac aac cct tgc tcc gaa gtg tac cat gga ccc cac gcc aat tcg gaa 865
Asp Asn Pro Cys Ser Glu Val Tyr His Gly Pro His Ala Asn Ser Glu
255 260 265

gtg gag gtg aaa tca gtg gta gat ttc atc caa aaa cat ggg aat ttc 913
Val Glu Val Lys Ser Val Val Asp Phe Ile Gln Lys His Gly Asn Phe
270 275 280 285

aag tgc ttc atc gac ctg cac agc tac tcg cag ctg ctg atg tat cca 961
Lys Cys Phe Ile Asp Leu His Ser Tyr Ser Gln Leu Leu Met Tyr Pro
290 295 300

tat ggg tac tca gtc aaa aag gcc cca gat gcc gag gaa ctc gac aag 1009
Tyr Gly Tyr Ser Val Lys Ala Pro Asp Ala Glu Glu Leu Asp Lys
305 310 315

gtg gcg agg ctt gc^g gcc aaa gct ctg gct tct gtg tcg ggc act gag 1057
Val Ala Arg Leu Ala Ala Lys Ala Leu Ala Ser Val Ser Gly Thr Glu
320 325 330

tac caa gtg ggt ccc acc tgc acc act gtc tta taaactgcc aactggag 1110

Tyr Gln Val Gly Pro Thr Cys Thr Thr Val Leu

335

340

atactcatca gattgctcca acagaagagg aggaaggctc tcccgaggc tgtccaggag 1170

acataaaatt tctacctttt ctttctttt tgaaatggag ttgcgttgc ctcttgtgc 1230

ccaggctgga gtgcaatggc gtgatctcca ctcatcgcaa cttccgcctc ccaggttcaa 1290

gcgattcccc tgcctcagcc tcccggat aa ctgggattat aggcatgtgc cccacccca 1350

actaattttt gtatTTTtag tagagatggg gtttctccat gttggtcagt ctggcttga 1410

gctcccgacc tcaggtgatc tgccgcctc ggcctctcaa agtgctggg ttacaggcgt 1470

gagccacagc acccggccaa aatgtccacc ttttctaaga gcccatcttc catattctt 1530

ataggccttg tctgtccttg tttttcaaaa aaaaaaaca a tcaattttt tataatagca 1590

ctctatccaa cgccataggt tatgggtgt gctacataca cagtcgacgt ttgtccttc 1650

aagtgctggg cctttccta gatgccatt ttagaggaaa ataattctaa aatggatttt 1710

acactttct gccttctaaa acagagcatg gagaagagat ttaagccct ttttcatgg 1770

ttaagtgtac ttctcaacct cagttcgtat atgctaaagg cctactctgc cgtttggac 1830

tgtttggacc ttctgctaaa tgatcctggc ctgtttct tcttgttgc ttgttgc 1890

gttttgttc tccttcctcc tgccagactg tcagcagtag ctgttattgc ttccaggccaa 1950

cagcctctag caacccttcc ccctcctt cactgattct gctccaggaa gggcttggaa 2010

acaagttctt tgggttcatc tgacttgtt gataacacagt ttcatgtact tttttagtt 2070

cataagcgtg gtgattgggt tttcacgctc atgtgtgaca tatgccttcc tccaattttt 2130

ttacaatgtt ggtgcgttac ccatcagaca tggggaaaga aagggttttc atgacagcat 2190

tatccatagt tacaaaagac atgtacaggg gccaaggaa aacttccct ttgccttgc 2250

aagggttcatc gaaaaatcaa ctgaccaaag gcagatcgat aggagaaaag gcataacaaa 2310

ttttatTTTA gtgtgcatttgg cacagggaa tcacaggaga atgatttccc aataacccaa 2370

tggggcacag aagcttgtat acccttttc atacaggagg gaggagatgt atggactggg 2430
gaggtgggag gcagatatta caggaaggta agggcggag ctgtacagga acaaagcttg 2490
tcttattaaag cagataaagt cctccaggca atctcttggta gctgctctca gaagaataga 2550
tgaagtctgt ctgggtgtgg tcatgattcc cagtcctatc tcttctggtg gtttatctt 2610
cttggttatt tcatgagacc tctaggagg gtgtttaaga caattgcatt tctttggaa 2670
agatgctttc ttggtcagat gagaaattt ccaaagacag acagtcctc cctgtgttg 2730
gtgggtgggc aggtatgggg aacaagaagt tagagggacc ttgggtcggtt ggcggcttct 2790
gagggccctc agcatgtcaa aacatcagcc tttggatat cacttctga gccccaaccc 2850
ttgttaagtgt ctaaaatgtc cacctagaga atgcaggata aatacacatt tggtgcattc 2910
acacaatgca gcactacgga gcccttaaat gaatgaggta gatctatgtg cgctaaaagg 2970
gaataactcac caattgttaa ttgaaaaata catgtgcaga acagcgtaa tagtgttttc 3030
ccatTTTTG ttgttggat tgTTTTAA gagtaggtg actttcagca gggacccaaa 3090
taaagtgaag tttacaaact tcgtcattt gactgaaaaa aaaaaaaaaa aaaaaaaaaa 3150
aaaaaaaaa 3156

<210> 15

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Primer

<400> 15

cgattgaatt ctagacctgc ctcgagnnnn nnnnn

<210> 16

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Primer OC001-F1

<400> 16

gtccttcagc aaaacagtgg atttaaa

27

<210> 17

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Primer OM237-F1

<400> 17

ccagaaaagca cagccctgat tctgcgt

27

<210> 18

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Primer OA004-F1

<220>

<221> modified base

<222> 1

<223> biotin conjugated base

<400> 18

atgcacatct tcaaggatgc tcag

24

<210> 19

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Primer OAF075-F1

<400> 19

ccccggggac atgaggtgga tactgtt

27

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

NOVEL POLYPEPTIDES, cDNA ENCODING THE SAME, AND USE OF THEM

the specification of which is attached hereto unless the following box is checked:

was filed on _____ as United States Application Number or PCT International Application Number _____ and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information of which is material to the patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed		
P. Hei. 10-131815 (Number)	Japan (Country)	14/May/1998 (Day/Month/Year Filed)
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)

I hereby claim the benefits under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

_____ (Application Number)	_____ (Filing Date)
-------------------------------	------------------------

I hereby claim the benefits under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

_____ (Application Number)	_____ (Filing Date)	_____ (Status - patented, pending, abandoned)
-------------------------------	------------------------	--

_____ (Application Number)	_____ (Filing Date)	_____ (Status - patented, pending, abandoned)
-------------------------------	------------------------	--

30 I hereby appoint John H. Mion, Reg. No. 18,879; Thomas J. Macpeak, Reg. No. 19,292; Robert J. Seas, Jr., Reg. No. 21,092; Darryl Mexic, Reg. No. 23,063; Robert V. Sloan, Reg. No. 22,775; Peter D. Olexy, Reg. No. 24,513; J. Frank Osha, Reg. No. 24,625; Waddell A. Biggart, Reg. No. 24,861; Louis Gubinsky, Reg. No. 24,835; Neil B. Siegel, Reg. No. 25,200; David J. Cushing, Reg. No. 28,703; John R. Inge, Reg. No. 26,916; Joseph J. Ruch, Jr., Reg. No. 26,577; Sheldon I. Landsman, Reg. No. 25,430; Richard C. Turner, Reg. No. 29,710; Howard L. Bernstein, Reg. No. 25,665; Alan J. Kasper, Reg. No. 25,426; Kenneth J. Burchfiel, Reg. No. 31,333; Gordon Kit, Reg. No. 30,764; Susan J. Mack, Reg. No. 30,951; Frank L. Bernstein, Reg. No. 31,484; Mark Boland, Reg. No. 32,197; William H. Mandir, Reg. No. 32,156; Scott M. Daniels, Reg. No. 32,562; Brian W. Hannon, Reg. No. 32,778; Abraham J. Rosner, Reg. No. 33,276; Bruce E. Kramer, Reg. No. 33,725; Paul F. Neils, Reg. No. 33,102; Brett S. Sylvester, Reg. No. 32,765 and Robert M. Masters, Reg. No. 35,603; my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and request that all correspondence about the application be addressed to SUGHRUE, MION, ZINN, MACPEAK & SEAS, PLLC, 2100 Pennsylvania Avenue, N.W., Washington, D.C. 20037.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

00 Date October 17, 2000 First Inventor Daikichi FUKUSHIMA
First Name Daikichi Last Name Fukushima
Residence Osaka, Signature Daikichi Fukushima
Japan Post Office Address c/o Minase Research Institute, ONO Pharmaceutical Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, OSAKA 618-8585 JAPAN JPX
Citizenship Japan

2-00 Date October 17, 2000 Second Inventor Shiro SHIBAYAMA
First Name Shiro Last Name Shibayama
Residence Osaka, Signature Shiro Shibayama
Japan Post Office Address c/o Minase Research Institute, ONO Pharmaceutical Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, OSAKA 618-8585 JAPAN JPX
Citizenship Japan

3-00 Date October 17, 2000

Third Inventor Hideaki

First Name

TADA

Middle Initial

Last Name

Residence Osaka,

Signature Hideaki

Tada

Japan

Post Office Address c/o Minase Research Institute, ONO Pharmaceutical
Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho,
Mishima-gun, OSAKA 618-8585 JAPAN SPX

Citizenship Japan

Date _____ Fourth Inventor _____

First Name

Middle Initial

Last Name

Residence _____

Signature _____

Post Office Address _____

Citizenship _____

Date _____ Fifth Inventor _____

First Name

Middle Initial

Last Name

Residence _____

Signature _____

Post Office Address _____

Citizenship _____

Date _____ Sixth Inventor _____

First Name

Middle Initial

Last Name

Residence _____

Signature _____

Post Office Address _____

Citizenship _____

Date _____ Seventh Inventor _____

First Name

Middle Initial

Last Name

Residence _____

Signature _____

Post Office Address _____

Citizenship _____

Date _____ Eighth Inventor _____

First Name

Middle Initial

Last Name

Residence _____

Signature _____

Post Office Address _____

Citizenship _____

(Supply similar information for ninth and subsequent joint inventors.)